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CHAPTER I 
INTRODUCTION 
A. Neurotransmission and Dementia 
1. Neurotransmission in Synapses 
Neuronal systems can be quite complex regulating an array of 
physiological functions through the interaction of sequentially coupled nerve 
cells that use different neurotransmitters. A neurotransmitter (a chemical 
messenger released from neurons into a synapse) can be excitatory in one 
system but inhibitory in another. For example, sympathetic ganglia have been 
shown to contain three kinds of receptors, as shown in the schematic diagram 
in Fig. 1. 
Preganglionic 
Fiber 
SIFN 
Postganglionic 
Fiber 
Figure 1. Interaction between neurons in a sympathetic ganglion. DA, dopaminergic 
receptor; M, muscarinic cholinergic receptor; N, nicotinic cholinergic receptor; A Ch, 
acetylcholine; SIFN, small intensely fluorescing interneuron (Ryall, 1979). 
1 
2 
Sympathetic ganglia, which normally operate on a cholinergic 
mechanism, also include small, intensely fluorescing neurons (SIFN) that 
produce dopamine and hyperpolarize the postganglionic neuron, thereby 
establishing a complex control system. A preliminary understanding of the 
sequential coupling of neurons now permits a discussion of the treatment of 
pathological states due to neuronal dysfunction. As an example, Fig. 2 briefly 
diagrams the pathophysiology of Parkinson's disease, a degenerative syndrome 
characterized by neuromotor disorders such as tremor, rigidity, a stooped 
posture, and difficulty in initiation and stopping movement. 
Motor neuron 
Striatum Substantia 
Nigra ) ~,-, I ' - - - - - - - - - - 7 DA ' \ I 
' , 
... - ; 
Figure 2. Neuronal networks. The motor neuron in the striatum is regulated by an 
excitatory cholinergic neuron and an inhibitory dopaminergic neuron, which in turn is 
influenced by a GABAergic fiber. Loss of the dopaminergic nigrostriatal fibers leads to 
excessive cholinergic stimulation of the motor neuron, resulting in Parkinson's disease. 
3 
Parkinson's syndrome results from the disappearance of dopaminergic 
neurons connecting the substantia nigra with the striatum. The loss of 
dopaminergic inhibition in the stria tum causes cholinergic hyperactivity in this 
brain region, resulting in many of the neuromotor symptoms of the disease. 
Representative drug treatment for Parkinson's disease, therefore, consists of 
a combination of dopamine replacement and release facilitation therapies, as 
well as the use of cholinergic blocking agents to control parasympathetic 
hyperactivity. 
2. Drug Development for Senile Cognitive Decline 
The treatment of senile cognitive decline is one of the greatest 
challenges for the mental health sciences today. No truly effective therapy has 
yet been launched although research in the cognitive sciences has the potential 
to produce enormous personal, medical and cost benefits. For the many 
scientists working to find a cognition activator with strong effects, the risk lies 
in the possibility that senile cognitive decline may not be treatable. 
Dementia is a clinical syndrome involving reduced intellectual 
functioning with impairments in memory, language, visuospatial skills, and 
cognition including deficits in mathematics, abstraction, and judgement 
(Cummings, 1980). Currently, several forms of dementias such as multiinfarct 
dementia (MID), extrapyramidal disorders (EPS), depression, etc. have been 
treated (Cummings, 1985), but others cannot be treated, most notably primary 
4 
degenerative dementia (PDD; also called senile dementia, senile dementia of 
the Alzheimer type, Alzheimer's disease, organic brain syndrome). The original 
diagnosis of PDD was made in 1907 by Alois Alzheimer and the relationship 
between normal aging of the brain and PDD remains unresolved. PDD was 
considered a medical curiosity for many years. However, the magnitude of its 
occurrence, especially in the elderly, has only been recently appreciated. The 
etiology and pathogenesis of PDD is presently unclear, however, a number of 
factors have been hypothesized to be involved (Table I; Wurtman, 1985). 
Table I. Possible Causes of PDD 
• genetic factors 
• abnormal protein models 
• infectious agents 
•toxins 
• blood flow disorders 
• cholinergic hypothesis 
• multiple factors 
Within the last few decades, the focus of PDD research has shifted to 
biochemical and neurochemical approaches, with the hope of identifying agents 
that improve the behavioral endpoints of learning and memory by a defined 
mechanism of action. Present strategies include cholinergic agents (Table II), 
analogues of ACTH (adrenocorticotropin), vasopressin and somatostatin (Table 
III), serotonin agents, and adrenergic agents (Table IV). 
Table II. Cholinergic Agents 
0 
II 
MeNHCO 
Me 
arecoline physostigmine 
Flood, 1985; Mutschler, 1984; Mohs, 1985; Christie, 1981; 
Brinkman, 1983; Jotkowitz, 1983; Davis, 1982; Beller, 1985 
0 
N 
I 
Me 
RS-86 
0 
Wettstein, 1984 
Ac Me 
bethanecol BM-5 
Harbaugh, 1984 Nordstrom, 19~ 
5 
) 
6 
At present, the most widely accepted biochemical hypothesis involves the 
cholinergic system. PDD patients contain specific biochemical and 
histopathological changes in the cholinergic system. These observations 
suggest that new approaches are possible to develop animal models for senile 
cognitive decline. 
Since the average age of the population is on the increase, the frequency 
of Alzheimer's disease is increasing rapidly, thereby requiring urgent attention 
(Goodnick, 1984). 
Table III. Analogues of ACTH, vasopressin, and somatostatin 
Met(S=O)-Gln-His-Phe-Lys-Phe 
ORG 2766 
S-(CH2 ) 2C(=O)-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-GlyNH2 
DDAVP 
HCys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-OH 
DGAVP 
(N-Me)Ala-Tyr-D-Trp-Lys-Val-Phe 
L 363,586 
Nicholson, 1984 
Jolkkonen, 1985 
Nyakas, 1985 
Beckwith, 1984 
Stein, 1984 
Peabody, 1985 
Jennekens-Schinkel, 1985 
cutler, 1985 
7 
Table IV. Serotonin and adrenergic agents 
Dehlin, 1985 ; Bergman, 1983 
alaproclate 
Br 
Cutler et al., 1985 
zimelidine 
Cl;Q 
H I C>=·::,.. N Cl Arnsten, 1985 
H 
clonidine 
B. Acetylcholine and Cholinergic Receptors 
1. Acetylcholine (ACh) 
1.1. Structure 
8 
The cholinergic neuronal system can be found in the central nervous 
system (CNS; especially in the cortex and caudate nucleus), in the autonomic 
nervous system, and in the skeletomotor system. Acetylcholine (2-(acetoxy)-
N ,N ,N-trimethylethanaminium ion; ACh) is the major neurotransmitter in the 
ganglia, the neuromuscular junction, and the postganglionic synapses of the 
cholinergic (parasympathetic) nervous system. Like most neuronal systems, 
cholinergic receptors show duality, and are distinguished as nicotinic and 
muscarinic receptors, which differ in many respects. Whereas acetylcholine (1) 
binds to both types of receptors, the plant alkaloids nicotine (2) and muscarine 
(3) trigger a response either from the nicotinic or muscarinic cholinergic 
receptors, respectively. 
0 CH3 II 1+ 
/'-._ ./'-... ✓ N-CH3 H C o' "-/ ' 
3 CH 3 
N 
Acetylcholine 
1 
H 
Nicotine 
2 
HO" 
,,,,. CH 
+1 3 
N-CH 
HC CH_,....' 3 3 0 2 CH 
3 
cis-(+)-Muscarine 
3 
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1.2. Conformation of ACh 
Owing to free rotation about the N-CH2-CH2-O side chain of 
acetylcholine, conformational isomerism must be considered an important 
determinant in assessing the interactions with different receptors, such as the 
nicotinic, the muscarinic, and the acetylcholinesterase (AChE; the enzyme 
responsible for maintaining the proper titer of ACh) receptor surface. 
Much interest has been focused on the relationship of the torsion angle 
of the N-C-C-O ester fragment (t2) to the bioactivity (Fig. 3). The role of the 
torsion angle to muscarinic activity has been thoroughly examined (Portoghese, 
1970; Pullman, 1972; Beveridge, 1973; Bergmann, 1974; Casy, 1975; Snyder, 
1985). Among the many possible conformations, two predominant forms, the 
gauche and anti, should be considered. 
CH T 2 0 
+· 3 E .. CH -N-cH CH -o-c-cH 3 , 2 2 3 
CH3 
gauche 
+ 
B~~J 
H~H 
OSCH3 
0 
anti 
Figure 3. Structure and major conformations of acetylcholine 
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X-ray and NMR studies (Jagner, 1977; Partington, 1972; Casy, 1975) 
show that the N-C-C-O grouping of acetylcholine exists predominantly in the 
gauche conformation (Fig. 3). More detailed studies on the conformation of 
ACh and its relationship to biological activity will be discussed in Sect C.2.4. 
1.3. Metabolism, Release, and Storage of ACh 
Investigations of ACh metabolism have been studied using 
radioimmunoassay (Spector et al., 1978) and pyrolytic gas chromatography. 
These techniques can detectACh at the femtomolar (lo-15M) level sensitivities. 
Acetylcholine is synthesized by the following reaction (Eq. 1): 
ChAT 
Choline+ Acetyl-CoA Acetylcholine + CoA-SH (1) 
Here, choline is acetylated by acetyl-CoA as mediated by the enzyme, choline 
acetyltransferase (ChAT). Acetyl-coenzyme A (CoA) is ubiquitous and choline 
is obtained either from phosphatidyl choline (lecithin) or free choline. Some 
choline 1s obtained via recycling surplus ACh hydrolyzed by 
acetylcholinesterase (AChE) (Fig. 4). There also is a high-affinity transport 
system (Km= 1-5 M) for choline reuptake in the nerve endings, which can be 
inhibited by hemicholinium (4). Unlike most other neurotransmitters, 
however, ACh itself is not taken up by active transport into synapses. 
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A B 
er 
ACb 
--- ·----► 
l 
D C 
er er 
-
Asp7 0 
0 
~ choline 
E F 
-o-cH2-ser Ser 
I 
A 
Figure 4. Mechanism of acetylcholine hydrolysis by acetylcholinesterase. 
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As ACh is synthesized, it is stored in the neuron or ganglion in at least 
three different states. Eighty-five percent of all A Ch is stored in a "depot", and 
can be released by neuronal stimulation. It is always the newly synthesized 
neurotransmitter that is released preferentially. The "surplus" ACh can be 
released by K+ depolarization only. Finally, there is "stationary" ACh, which 
cannot be released at all. 
Whittaker (1986) has shown that synaptic vesicles are metabolically 
inhomogeneous, and those closer to the presynaptic membrane release ACh 
preferentially. Several alternative hypotheses on ACh release have been 
proposed. One proposal assumes a voltage-dependent Ca+ reflux that opens 
a gate, allowing cytoplasmic ACh release for a timed period. A second proposes 
the containment of ACh in the smooth endoplasmic reticulum, in association 
with the presynaptic membrane. There is still much to be learned regarding 
the precise mechanism of ACh release (Tauc, 1982; Dunant and Israel, 1985). 
2. Acetylcholine Receptor 
2.1. Anatomy 
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The acetylcholine receptor (AChR) is one of the most thoroughly 
characterized components of the neuromuscular transduction process. Earlier 
reviews that summarized the structural and biochemical features of the AChR 
include those by Karlin (1980), Conti-Tronconi & Raftery (1982), Stroud (1983), 
and Popot & Changeux (1984). The AChR receptor translates the binding of 
the neurotransmitter, acetylcholine (ACh), into a rapid increase and 
subsequent decrease in the permeability of the endplate membrane to the 
passage of Na+ cations. The availability of acetylcholine receptors from electric 
tissues (e.g., Torpedo californica, Electrophorus electricus, and Torpedo 
marmorata) was a fundamental key to molecular characterization. The 
subunit stoichiometry of the four identified polypeptides has been 
unequivocally established as u2Byo, and the funnel shape of the molecule has 
been well characterized with respect to the position of the ion channel 
(McCarthy, 1986). 
2.2. Binding Sites 
The number and importance of different agonist binding sites on the 
AChR remains a matter of some controversy. A majority of studies indicate 
the presence of two, high-affinity ACh binding sites per AChR monomer in 
Torpedo californica localized on the u subunit (Conti-Tronconi & Raftery, 1982; 
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Popat & Changeux 1984). Several reports showed that these sites may not be 
initially equivalent (Weill, 1974; Damle, 1978; Weiland, 1979). Two classes of 
a subunits that differ in the extent of glycosylation have been observed in T. 
californica AChR (Conti-Tronconi et al., 1984). These differences may 
contribute to the nonequivalence of the high affinity agonist binding sites. 
Although these sites may not be identical in structure, both are involved in 
channel opening. 
The location of agonist binding sites remains a topic of great interest. 
The bulky, quaternary amine head group of the agonist probably binds to a 
sterically-restricted, anionic region on the receptor, while hydrogen bond 
formation between the carbonyl of ACh and the receptor AChR lend additional 
binding energy (Spivak and Albuquerque, 1982). 
C. Stereochemistry and Conformation of Drug-receptor Interaction 
l. General Aspects 
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One of the principle goals in pharmacology and medicinal chemistry is 
to adequately describe the molecular dynamics of the interactions between a 
drug and its receptor(s). These interactions exist in a system in which two 
components are essential: (1) the precise structure of the drug, and (2) the 
structure of the binding site(s) of the receptor macromolecule with which the 
drug interacts. Since all receptors are topologically defined, any description 
of a pharmacophore or drug must be three dimensional. As long as detailed 
stereochemical information on receptors is lacking, a logical step is to look at 
the stereochemical anatomy of the drug molecules interacting with a given 
receptor. In this manner, certain 3-D complementary features of the receptor 
can be gleaned. A great deal of effort has, therefore, been devoted to studying 
the relationship between stereochemistry and the active conformation of 
flexible drug molecules that trigger the response. 
One approach to the study of conformational selectivity at drug receptors 
has been the evaluation of preferred (lowest energy) conformation of the 
isolated molecule (quantum chemical, and empirical or force field calculations), 
of the molecule in the crystal state (X-ray crystallography), and of the molecule 
in solution (NMR spectroscopy). But attempts to deduce the receptor-active 
conformation of flexible drug from these studies alone are meaningless. 
Whether the methodology is theoretical, crystallographic, or spectroscopic, the 
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studied environment (vacuum, crystal, or solution) generally neglects possible 
higher energy and tight binding conformations that can occur in the flexible 
drug molecule through interaction with the receptor. Such possible 
conformations have generally been ignored, focusing on the energetically most 
stable conformer (Portoghese, 1970; Reed 1981). 
Ariens (1984) outlined and elucidated the significance of stereochemistry 
in therapeutic action and the role of enantioselectivity in 'hybrid' drugs (Ariens 
1986). Stereoisomerism and drug action (Lehmann 1986) has also been 
reviewed. Even earlier, the significance of stereoselectivity and affinity in 
molecular pharmacology was perceived in detail by Lehmann et al. (1976). A 
number of reports on substrate dependent enantioselective metabolism of 
chiral CNS agents, autonomic and cardiovascular agents, and miscellaneous 
drugs and xenobiotics were also reviewed (Low et al., 1978). 
2. Rigid or Semi-rigid Drug Analogues 
2.1. Methods of Reducing Conformational Flexibility 
Four different techniques of controlling the geometry of a flexible drug 
molecule, and of restricting rotations within the molecule may be used. 
Making use of steric factors; The freedom to rotate about a a-bond may be 
limited if the atoms forming a bond have large groups attached to them. In 
extreme cases, as with some di-ortho-substituted biphenyls, the rotation is 
17 
sterically restricted to give two distinct optical enantiomers. The use of this 
approach was documented in a series of diphenhydramines (Harms et al., 
1960). The authors investigated whether the ortho substituents weaken 
antihistaminic activity by interfering with the possibility for the flexible side 
chain to take the curled up position, which in the rigid structures mentioned 
is associated with high activity (e.g., orphenadrine and neo-benodine). These 
studies were conducted in view of the fact that several very active 
antihistaminics possess completely rigid or semi-rigid structures, the side 
chain either being fixed to one of the rings (phenindamine), or able to rotate 
around one axis only (chlorocyclizine). 
Cl 
Phenindamine 
Diphenhydramine 
Chlorocyclizine ortho-; Orphenadrine para- ; Neo-benodine 
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Making use of bioisosterism; Bioisosters are substituents or groups that have 
chemical or physical similarities that can produce broadly similar biological 
properties (Thornber, 1979). There are several literature studies in which the 
principles of bioisosterism were used to deduce stereostructure-activity 
relationships. A selected few are listed in Table V. 
Table V. Making use of bioisosterism 
Choline isologs 
Homocholine isologs 
where, B = o, s, Se 
R -H, -CH 3 , -C0CH 3 
+ (CH 3 ) 3N CH2CH 2C(O)CH 3 
r-
where, A 0, s 
B 0, S, Se 
A 
II 
c 6H5CBCH2cH2NR2 
where, A 0, S, Se 
B 0, S, Se, NH 
Webb et al., 1966 
Jagner and Jensen, 1977 
Makriyannis et al., 1972 
Chidichimo and Russo, 1977 
Pullman and Courriere, 1972 
Aldrich, 1975 
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Making use of multiple bonds; The relative positions of atoms attached 
directly to multiple bonds are fixed. In the case of double bonds, cis and trans 
isomers results (Table VI). The fixed geometry of the alkene differs greatly 
from the conformational freedom inherent in the corresponding alkane 
structure. 
Table VI. Making use of multiple bonds 
CH 
I 
(CH2)2 
I 
,, N, 
H3C CH3 
2-cbloro-9-(w-dimetbylaminopropyliden)thioxanthene 
Br 
zimelidine 
Et Et 
\ I 
~c=co 
HO OH 
cis- and trans- Stilbestrol 
cis- and trans- 4-Aminocrotonic acid 
Dunitz, 1964 
Ross, 1977 
Coppen et al., 1979 
Brown et al., 1980 
Solmssen, 1945 
Johnston et al., 1975 
Allan et al., 1980 
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Making use of cyclization; The conformational mobility of flexible drugs can 
be further reduced by incorporating various parts of the molecule into a ring 
structure. It is a simple matter to find rigid or semi-rigid skeletons into which 
the essential structure of drugs (the appropriate functional groups for potential 
activity) may be incorporated, and a lot of attention has been focused on the 
receptors of acetylcholine (Sections, B.2.2. and C.2.4.). 
2.2. Advantages of Controlling the Geometry of Flexible Drugs 
The major advantages of controlling conformational flexibility are: (1) 
the configuration of the active pharmacophoric conformation can be 
determined; (2) the key functional groups are rigidly held in one position, and 
a semi-rigid structure constrains these groups to certain values. Within a set 
of rigid or semi-rigid analogues, it is assumed that only those which fit the 
receptor will be active. In certain cases, stereochemistry is exclusively 
responsible for the differences in the degree of biological activity between the 
flexible parent drug and the constrained derivatives. From a comparison of the 
stereochemistry of the active analogues with possible conformations of the 
original drug, we can obtain information about which of the conformations of 
the parent substance reacts with the receptor and about the barriers to 
conformational alteration during drug-receptor interaction. 
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2.3. Disadvantages and Limitations of Controlling the Geometry 
of Flexible Dru.gs 
The use of conformationally constrained analogues of flexible drug 
molecules to investigate the participation of conformational isomerism in drug 
activity appears to be a feasible approach, although it is not without pitfalls. 
It is very difficult, if not impossible, to control the geometry of a flexible drug 
without also changing some other physico-chemical properties of the prototype 
drug. To produce a conformationally constrained analogue, new atoms and/or 
bonds must be added, and this may impart different chemical and physical 
properties, which must be taken into consideration when interpreting 
subsequent biological data. There is another problem in relating 
conformational isomerism with biological activity using rigid or semi-rigid 
analogues. Rigidity may deny a molecule the opportunity of undergoing a 
necessary conformational change during its interaction with the receptor. 
Therefore, analogues representing a highly rigid conformer could furnish 
misleading results when some degree of flexibility is needed for ideal 
interaction with the receptor. This feature is best described as mutual 
adaptability (Bergmann, 1974). 
Beers and Reich (1970) and Burgen (1975) proposed that molecular 
flexibility finds expression in the kinetic parameters of drug-receptor 
interaction. Lass et al. (1979), studying the time course of the action of 
muscarinic antagonists in carp atria, found that the dissociation of rigid 
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antagonists was very much prolonged as compared to flexible drugs of the 
same affinity. By way of contrast, Wassermann et al. (1979) reported that 
structure flexibility plays no role in the mechanism of action of acetylcholine 
at its receptor. In Wasserman's study, highly constrained depolarizing ligands 
were used. 
2.4. Studies with Cyclic Analogues of ACh 
Schueler (1956) first drew attention to the possibility that muscarinic 
and nicotinic effects due to ACh are mediated by different conformational 
isomers of the molecule. He examined the N,N-dimethyl-3-acetoxypiperidine 
(5) and the morpholine derivative (6) as models of antiplanar and synclinal 
N/0 conformations of ACh, respectively. Both were feebly active in muscarinic 
and nicotinic assays, with (5) showing greater potency. 
5 
~o 
Me-~~ 
I ~ 
Me O 
6 
Cannon's group chose the cyclopropane ring as the smallest system 
capable of conferring conformational and configurational rigidity on an ACh 
analogue (Armstrong, 1968; Chiou, 1969), and succeeded in obtaining an 
24 
isomer that had a high muscarinic potency. 
+ 
xe-c ~-, 
0 0 
7 8 
( + )-Trans-2-acetoxycyclopropyltrimethyl ammonium iodide (ACTM) (7) 
equalled or surpassed ACh in two biological test systems. Interestingly, the 
enantiomer (-)-trans-ACTM was several hundred times weaker than the (+)-
form while the racemic cis isomer (8) was virtually inactive. Cyclopropyl and 
cyclobutyl derivatives (9 - 11) have also been examined (Cannon, 1972, 1973) 
as analogues of acetyl y-homocholine or 4-acetoxybutyltrimethyl ammonium, 
but provided no useful data relevant to the active conformation of ACh. 
0 + 
II R y. <)fNMe3 MeCOCH2v. 
CH20CMe OCMe II II 
0 0 
9 10 11 
+ + 
R = NMe3 or CH2NMe3 
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Some cyclohexyl analogues of ACh are illustrated in Table VII. More 
cyclic analogues of ACh will be introduced in the following section as cyclic 
imonium ions. 
Table VII. Cyclohexyl derivatives of acetylcholine 
0 
+~~Me 
Me-N 
I 
+ Me-N 
I 
Me OCMe 
II 
0 
Lewis et al., 1973 
Baldridge, 1955; Friess, 1956 
+ 
R • H, 2-Me, 3-Me, and 4-Me 
(where R - Me, cis and trans 
isomers separated) 
a) A= OC(O)Me, B • NMe3 
Biggs, 1972 
B 
b) A• NMe3, B • OC(O)Me 
Chittenden, 1970; Ahmad, 1971; 
Cooper, 1971; Beckett, 1971 
a) A= OC(O)Me, B = H 
b) A= H, B • OC(O)Me 
Nelson, 1971; Beckett, 1972 
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D. Aziridinium Analogues 
l. Aziridinium (Ethyleneinwnium) Cation 
The aziridinium cation was recognized as the key intermediate in 
chemical reactions of nitrogen mustards, f3-haloethyl-tert-amines and as their 
pharmacologically active species in alkylating functional groups of compounds 
of biological importance, particularly, in adrenergic blocking and in 
antiadrenaline and antihistamine activity (Gilman and Philips, 1946; Golumbic 
et al., 1946). 
The majority of the nitrogen mustards are bis(f3-chloroethyl)amines, the 
third valence of nitrogen being occupied by one of a variety of alkyl groups. 
The rate of cyclization and the activity of the aziridinium cation is influenced 
by certain substituent groups on the molecule. A large number of nitrogen 
mustards of different physicochemical and pharmacological properties have 
been prepared. Thus, the scope of future investigations on the relationships 
between chemical constitution and pharmacological action of the nitrogen 
mustard is broad. 
It is useful to first describe the fundamental properties and formation 
of the aziridinium species. In pure aqueous solutions at physiological pH the 
aziridinium cation reacts with H2O (Fig.5). However, if other substances, 
namely nucleophiles are present, they can react competitively. More detail 
regarding this reaction will be discussed in Chapter III. 
bis ( 13 -chloroethyl) amine 
J> 
R-N Cl-
\ 
/CH2CH20H 
R-N 
\ 
CH2CH2Cl 
Figure 5. Reaction of aziridinium cation with water. 
2. Acetylcholine Mustard Analogues 
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The first synthesis of acetylcholine mustard (AChM) can be attributed 
to Hanby and Rydon (1947), and its toxicology and other nitrogen mustard 
analogues of choline can be credited to Anslow et al.(1947). Jackson and Hirst 
(1972) modified the synthesis procedure to obtain a higher yield, and showed 
clearly that the biological activity of AChM was due to formation of the 
aziridinium ion in a polar solvent. Comprehensive investigations of a variety 
of aziridinium analogues of choline and acetylcholine were reported by Clement 
and Colhoun (1974), Rylett and Colhoun (1977; 1979; 1980a,b; 1985). 
28 
3. Ethylcholine Mustard kiridinium; AF64A 
Much information has been provided over recent years showing the 
importance of specific neurotransmitters to study the etiology of various 
neuropsychiatric diseases. To understand neurotoxins in a particular 
neurotransmitter system in vivo, a number of attempts have been explored 
utilizing compatible neurotoxins. Such agents would be extremely valuable on 
two levels. First, they could be used to mimic specific neurotransmitter deficits 
shown to occur in certain disease states (e.g., dopamine in Parkinson's disease; 
acetylcholine in Alzheimer's disease), and thus attempt to reproduce the 
biochemical abnormality. Second, neuron-specific neurotoxic agents could 
serve as chemical probes in the study of basic mechanisms pertaining to the 
synthesis and metabolism of the affected neurotransmitter system, in vivo 
(Hanin et al., 1987). This Hanin group's suggestion implies the requirement 
of synthesis of a compatible, neuronspecific neurontoxin. 
Under normal circumstances, the rate of neuronal metabolism and 
turnover of ACh is extremely rapid, much faster than any of the other known 
neurotransmitters. Therefore, the cholinergic system generally is highly 
resistant to imitate. For this reason, studies of events at the cholinergic nerve 
terminal have been difficult, particularly when conducted in the intact 
mammalian system. Available pharmacological agents that have been able to 
perturb the cholinergic system in vivo, whether as agonists (e.g., cholinesterase 
inhibitors, pilocarpine, arecoline, oxotremorine, etc.) or antagonists (e.g., 
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atropinic agents, hemicholinium-3, etc.), usually have a limited period of action 
(hours or fractions thereof). Such agents have been useful as tools in 
evaluating acute responses and charges at the cholinergic nerve terminal. 
However, considering the study on the consequence of long-term cholinergic 
perturbation in vivo, these agents are of less use. A long-acting neurotoxin 
would be extremely valuable for this purpose. Furthermore, it could simulate 
the condition believed to exist in the case of Alzheimer's disease, i.e., a long-
term, persistent cholinergic hypofunction in the central nerve system (Hanin 
et al., 1987) 
Fisher and Hanin (1980) introduced AF64A (Ethylcholine Mustard 
Aziridinium, ECMA, 12) as a cholinergic neuronspecific neurotoxin and Hanin 
and colleagues later demonstrated 
that this compound may have 
selective cholinergic actions in the 
central nervous system of mice and 
rats (Fisher, 1983; Hanin, 1983; 
Mantione, 1981, 1983, 1984). 
Treatment with ECMA and ACh 
12 
mustard analogues in vivo simulate the neurochemical conditions that appear 
to cause a number of neuropsychiatric diseases including Alzheimer's disease, 
have been reported (Curti, 1984; Sandberg, 1985; Mistry, 1986; Pittel, 1987; 
Laganiere, 1990). 
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4. Mechanism of Action of AF64A 
Unlike the noncovalcnt ACh-AChR interaction, the highly strained 
three-membered ring structure of AF64A causes a unique interaction with the 
receptor, by forming a new covalent bond between a carbon of its ring and 
nucleophilic functional group in the anionic locus. The initial attraction to the 
receptor is probably governed by electrostatic force interaction between charged 
species. The possible mechanism of blocking the binding site by the AF64A is 
illustrated in Fig.6. 
Whether the new covalent bond stays, or eventually breaks by other 
factors, the new covalent bond has a much longer life time compared to the 
native neurotransmitter, and its receptor binding state. 
( 
CH --;N ~) CH --CH2 --OH 
2, 2 
( 
CH2 
HO 
,,, ..... :~-.~-,,11-11 1-r .. ,,,,,,,,, ~ 
anionic 
locus 
His Ser 
( 
anionic 
locus 
HO 
Figure 6. Possible blocking mechanism of the AF64A in the receptor binding site. 
CHAPTER II 
STATEMENT OF GOALS 
Although AF64A received a great deal of attention as a selective 
cholinergic neurotoxin, there are still several aspects of the approach to be 
examined and developed. Therefore, we would like to support the needed 
information through the preparation of chiral derivatives with the hope that 
these supportive studies could be used in furthering the development of 
AF64A-based drugs and prodrugs. 
First, as mentioned earlier m the introduction, the importance of 
stereochemistry in a biological molecule can be discussed as related to this 
neuron-specific neurotoxin. In terms of structure, AF64A simply blocks the 
binding site of its receptor by formation of a new covalent bonding between a 
carbon of the aziridinium mustard ring and a nucleophilic moiety at the 
binding site. However, AF64A does not give any configurational or 
stereochemical information of the receptor binding site raising the question of 
which configurational isomer shows higher affinity/reactivity toward its 
receptor. Therefore, we wish to undertake the synthesis of heterospirocyclic 
mustard analogues of AF64A by imposing chiral center(s) on those analogues, 
in the hope of enforcing a distinct stereochemical environment upon the 
neurotoxins. 
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HO~+j 
L> 
AF64A R=HorOAc 
R' = Hor Me 
* : chiral centers 
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Second, as a charged small molecule, AF64A may have problems 
penetrating through the blood-brain barrier, and would be easily solvated and 
decomposed in the biological system before the molecule reaches the binding 
site. Hence, modifying our synthetic pathways, we can expand the size of 
analogues by attachment of a long side 
chain to render them recognized more 
easily. The additional hydrocarbon chain 
would provide enhanced lipophilicity that 
could possibly make the molecules 
penetrate the blood-brain barrier better. 
Finally, as an organic synthetic chemist, the author had a great desire 
to isolate spirocyclic aziridinium ion analogues rather than generating the 
reactive species in situ. The formation of aziridinium ion in buffer solution (in 
situ) gave somewhat inconsistent results from some research groups (see 
Chapter III) due to the instability of the aziridinium ion during the incubation 
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period. Obtaining purified salts of aziridinium analogues in itself would have 
great advantages of knowing the exact molar concentrations of these putative 
neurotoxins in biological assay (in vitro and in vivo). Although no stable, 
spirocyclic aziridinium analogue of AF64A has ever been prepared, the long 
term benefits of the goal are deemed highly significant. 
CHAPTER III 
PROJECT DESIGN AND TARGET MOLECULE SELECTION 
A. Cyclic Analogues of AF64A 
In order to focus the design and the construction of our target molecules, 
we first wished to study the structure of AF64A and collect detailed 
information related to the topography of this neurotoxin and related 
compounds. This approach would be an ideal starting point with the study 
extended to possible bi- or spiro-cyclic analogues. In case of bicyclic 
analogues, azabicyclo[3.l.0]hexanes (15 and 16) and azabicyclo[4.l.0]heptanes 
(19 and 20) are proposed (Fig. 7). On the other hand, as appropriate 
spirocyclic analogues, 5-hydroxy-3-azoniaspiro[2.4]heptanes (13 and 14) and 5-
hydroxy-3-azoniaspiro[2.5Joctanes (17 and 18) are proposed. From a molecular 
structural point of view, all of these analogues and AF64A show a common 
feature; namely, two carbons are located in between the nitrogen and oxygen 
atoms. However, the asymmetrical cyclic structure of these derivatives of 
AF64A furnishes each analogue with chirality. 
34 
HOb HO/✓,, "",, C) 
N N 
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spiropyrrolidines 
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17 18 
spiropiperidines 
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HO"Gb 
N 
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N 
HO 
I I 
Et Et 
15 16 
I 
Et 
[3.1.0] 
azabicyclohexanes 
HO11, 
,,.,,. 
+ 
N 
Et 
19 
[4 .LO] 
azabicycloheptanes 
20 
Figure 7. Proposed analogues of AF64A. 
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The proposed AF64A derivatives represent conformationally and 
configurationally set analogues. It is possible to estimate via computer 
simulations each minimized conformation, dihedral angle, and intramolecular 
atomic distance between the two heteroatoms, nitrogen and oxygen. We 
conducted molecular mechanics calculations on choline, AF64A, and three 
derivatives. The results are shown in Table VIII (PCMODEL, 1988 Version). 
Table VIII. Molecular mechanics calculations 
I ntramolecular Dihedral 
Molecule N-0 distance (A) angle (0 ) 
Choline (gauche rotomer) 3.01 57.43 
Choline (anti rotomer) 3.79 178.15 
AF64A (gauche rotomer) 3.00 63.39 
AF64A (anti rotomer) 3.74 174.62 
(S)-3-Hydroxyspiropiperidine 2.89 65.09 
mustard (17) 
(R)-3-Hydroxyspiropiperidine 3.71 175.23 
mustard (18) 
(S)-3-Hydroxy-[ 4.1.0]-aza-trans- 2.69 63.74 
bicycloheptane (19 trans) 
(R)-3-hydroxy-[ 4. 1.0]-aza-trans- 3.62 173.41 
bicycloheptane (20trans) 
(S)-3-Hydroxy-[ 4.1.0]-aza-cis- 2.95 66.47 
bicycloheptane (19 cis) 
(R)-3-Hydroxy-[ 4.1.0]-aza-cis- 3.72 170.50 
bicycloheptane (20 cis) 
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The gauche rotomers of choline and AF64A show identical 
intramolecular atomic distance between oxygen and nitrogen, and the anti 
rotomers show only a 0.05A difference in intraatomic distance. (S)-3-
Hydroxyspiropiperidine mustard (17) can be considered as a configurationally 
locked analogue of a gauche rotomer of choline or AF64A that deviates by only 
O.llA (in intraatomic distance from AF64A). This difference is much shorter 
than even the hydrogen atomic radius (0.53A). The (R)-isomer (18) also shows 
a well matched intraatomic distance when compared with the anti rotomers of 
choline and AF64A. The dihedral angle value of this isomer is even closer to 
the value of choline than that of AF64A. The bicyclic [ 4. I.OJ mustard 
derivatives were analyzed as cis and trans isomers relative to the 
stereochemistry of the ring junction. The cis isomers of (19) and (20) show 
similar intraatomic distances to (17) and (18), respectively. However, the 
dihedral angles of these derivatives show somewhat higher deviations. 
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B. Prior Studies on Pipericline-based ACh Analogues 
As mentioned in the introduction, conformationally rigid or semi-rigid 
analogues of flexible drugs can off er a powerful aid toward establishing the 
conformational and configurational requirements of pharmacological receptors. 
'Fliis, in turn, may lead to enhanced selectivity of current drugs, and the design 
\ 
/\\ 
of,inew active agents. Before we embark on a synthesis of the preliminary 
target molecules, we first should be aware of several studies performed earlier 
that could help us to design and construct our heterocyclic spiropiperidine 
mustard derivatives. In the following sections, we will describe how these 
studies relate to our proposed derivatives. 
l. 3-Acetoxypiperidine Derivatives 
With interest in study of the physiological neurotransmitter 
acetylcholine, Lambrecht and Mutschler (1979) investigated the muscarinic 
activities of piperidine derivatives as conformationally and configurationally 
fixed analogues of acetylcholine. First, they synthesized the tertiary and 
quaternary individual enantiomers ofN-methyl-3-acetoxypiperidine, and N,N-
dimethyl-3-acetoxypiperidiniums (21-24) and later tested these compounds for 
their muscarinic activities (Lambrecht and Mutschler, 1974a,b; Holtje, 1979; 
Lambrecht, 1976a,b; Lambrecht 1980). 
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ACOD AcOi,,,,,o AcOD Aco,,,,,,.() 
+ - + -
_,,....,N--..._ I 
_,,....,N '-- I N N 
H3C CH3 H3C CH 3 I I CH3 CH3 
21 22 23 24 
As shown in Table IX, all the semi-rigid analogues, based on the 
piperidine skeleton, were very weak muscarinic agonists. In this table, the 
pD2 value is a measure of muscarinic potency, and the higher value shows 
higher potency. The low muscarinic potency of these compounds might result 
from structural and stereochemical restrictions. Lambrecht and Mutschler 
forwarded two possibilities for these weak activities; (1) too much energy is 
needed for the cyclic analogues to reach the required muscarinic-essential 
conformation during agonist-receptor interaction, and (2) direct steric 
hindrance caused by the supporting structure of the compounds. 
Table IX. Muscarinic activities of cyclic acetylcholine 
analogues in the piperidine series. 
Compound 
Acetylcholine (1) 
(S)-N ,N-Dimethyl-3-acetoxy-
piperidinium iodide (21) 
(R)-N,N-Dimethyl-3-acetoxy-
piperidinium iodide (22) 
(S)-N-Methyl-3-acetoxypiperidine (23) 
(R)-N-Methy 1-3-acetoxypi peridine (24) 
7.51 
3.92 
3.40 
3.68 
2.99 
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These questions were also addressed, in part, by Mashkovsky (1963), 
who imposed further conformational restrictions on these piperidine 
compounds by an additional bridging ethylene resulting m 3-
acetoxyquinuclidines (25-28). 
crrOAc rn·•"''OAc CCYOAc ([)""'OAc 
N N N - N -I I 11 
CH3 CH3 
25 26 27 28 
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The formal representation of 3-acetoxyquinuclidine's ring system consists of 
three boat like structures of piperidine, where each boat shares the nitrogen 
and three other carbon atoms with the other's boats (Fig. 8). 
CH3 +/ 
H-N 
I\ ~ 
'--,-, -- OAc 
.,__ __ _,.
23 25 R = H 
27 R = CH3 
Figure 8. (S)-Boat conformation ofN-methyl-3-acetoxypiperidine (23) and the structure of the 
(S)-enantiomers of 3-acetoxyquinuclidines; R = H (25), CH3 (27). 
As shown in Table X, the tertiary quinuclidine esters (25 and 26) have 
considerable muscarinic potency, and the more potent (S)-enantiomer may be 
used as a model for discussing fit to the receptor. First, the high activity of the 
tertiary compound indicates that the parts of the quinuclidine ring, which are 
not present in acetylcholine, only slightly disturb the approach to, or the 
reaction with, the muscarinic receptor. Second, the muscarinic potency of the 
corresponding quaternary compounds (27 and 28) is much weaker, probably 
caused by steric hindrance due to the additional equatorial N-methyl group of 
the compounds. 
Table X. Muscarinic activities of cyclic acetylcholine analogues 
in the quinuclidine series. 
Compound 
Acetylcholine (1) 
(S)-3-Acetoxyquinuclidine (25) 
(R)-3-Acetoxyquinuclidine (26) 
(S)-3-Acetoxyquinuclidine methiodide (27) 
(R)-3-Acetoxyquinuclidine methiodide (28) 
'7.51 
6.10 
5.02 
3.97 
3.56 
42 
Mutschler's group (Gloge, 1966; Kummer, 1966; Konig, 1967; 
Christiansen, 1967) also investigated the corresponding inverse esters, namely 
methyl quinuclidine-3-carboxylate (29) and methyl N-methyl-piperidine-3-
carboxylate (dihydroarecoline; 30) and evaluated their muscarinic action. 
29 30 
These inverted esters showed very similar activities to their 3-acetoxy-
derivatives. This means that the constitution of the ester side chain is not 
important for their affinity in this case. It is also unimportant whether the 
structure contains the ester of an amino acid with an alcohol or with the ester 
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of an amino alcohol with a carboxylic acid. It is the rigid boat form of the 
quinuclidine ring which is the necessary characteristic for its activity. · 
Lambrecht and Mutschler's work suggested to us that our proposed 
spiropiperidine aziridinium analogues would show certain muscarinic 
activities. Also, we could opt to replace the hydroxyl group with an acetoxy 
group at the C3 position. Considering the high reactivity of the aziridinium 
ring, replacing the hydroxyl group with acetoxy group may permit these 
analogues to survive longer until they reach at the acetylcholine receptor sites 
without going through the interaction with acetyl CoA and ChAT to induce the 
acetylcholine analogues. 
2. Studies on Aziridinium-based Molecules Related to AF64A 
After Fisher and Hanin (1980) proposed that nitrogen mustard 
analogues of choline could be the cholinotoxins of choice for the development 
of animal models of human neurologic and psychiatric disorders involving the 
cholinergic system (e.g., Alzheimer's disease), some of the more than 126 
reports produced evidence for the cholinergic effect of AF64A in the CNS of 
rodents. A small number of investigators have found difficulties with use of 
AF64A, the most notable of which is nonspecific tissue damage at the site of 
injection, which could preclude the selectivity of its reaction. The general 
method of preparation of AF64A and its derivatives is shown in Scheme I 
(Mistry, 1986). 
Scheme I. Synthesis of AF64A 
ci-
[::1-t:..._ CH2CH20H a 
R 
a 1. NaOH/H20; pH 11.5 (30 min), 2. H20; pH 7.4 
R = Et (AF64A), n-Pr, i-Pr, cyclopropyl, n-Bu, i-Bu 
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1
CH2CH20Ac 
R-N 
\ 
CH2CH2Cl 
After the 2-[alkyl(2-hydroxyethyl)amino]ethyl acetates were obtained, 
cyclization to the desired aziridinium choline moieties was accomplished by 
alkaline hydrolysis of the acetylated compounds. This step can lead to 
discrepancies in dose and biological effect owing to incomplete conversion to 
aziridinium causing inconsistent results for some investigators. For example, 
formation of the nitrogen mustard required incubation of the (3-chloroethyl 
precursor at high pH (11.5) for up to 30 minutes. The longer the time the 
cyclized compound is maintained at alkaline pH, the less aziridinium ion will 
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be recovered since the aziridinium ion itself is susceptible to hydrolysis. Rylett 
and Colhoun (1980) found that such prolonged exposure to high pH is not 
necessarily required for hydrolysis of the acetoxy bond, and a lower pH 
accomplishes the desired effect. In their report, maintaining the mustard 
compound at pH 10.5-11.0 for 10 minutes is adequate for complete generation 
of the choline moiety. 
The transformation of mustard into aziridinium ion was detected by the 
iodine-thiosulphate titration method (Golumbic, 1946). The solvated 
aziridinium ion is unstable and decomposition, largely to the alcohol (Fig. 9, 
reactions 3 and 5), is both temperature and time dependent. At ambient 
temperature and neutral pH, the rate of decomposition of acetylcholine 
mustard aziridinium ion is 5% in 90 minutes (Jackson and Hirst, 1972). 
/CH2CH20H 
R-N 
' CH2CH2 0H 3 
0 
II /R 
CH3COCH2CH2N, 
CH2CH2Cl 
2 ! pH 11; 10 nin 
3 
5 
4 ! Nucleophile 
/CH2CH2 -Nu 
R-N 
' CH2CH2 0H 
0 
► dimers, polymers 
Figure 9. Structure and reaction scheme for nitrogen mustard analogues of choline. 
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As shown in Fig. 9, in aqueous solution, tertiary amines bearing the f3-
chloroethyl moiety undergo spontaneous intramolecular alkylation by 
reversible reaction 1 to yield the aziridinium ion and displaced c1- (Golumbic, 
1946). At ambient temperature and physiological pH, approximately 70% of 
the aziridinium is formed when 10 mg/ mL acetylcholine mustard is dissolved 
in water (Rylett, 1979). 
The cyclized quaternary amine produced is vulnerable to a number of 
ring opening reactions with the net result of lowering the effective 
concentration of biologically active compound in solution. These reactions 
include recombination with the leaving group halide to yield the tertiary amine 
(reaction 1), hydrolysis by reaction with water to yield the alcohol (reaction 3), 
alkylation of nucleophilic groups in the medium or biological tissue (reaction 
4), and reaction of the cyclized form with uncyclized tertiary mustard (3°) to 
give a number of dimers or polymers (reaction 5). Reactions 3 and 4 are the 
most common, with reaction 4 having the greater biological significance 
(Golumbic, 1946; Fruton, 1946a,b). 
In a previous section, we showed that an additional methyl group on 
quaternary piperidine derivatives causes significant lowering in muscarinic 
activity. Instead of those two methyl groups on quaternary piperidine, our 
proposed spiropiperidine derivatives possess two methylene groups which form 
the highly strained three membered aziridinium ring with the bridged nitrogen 
atom. Therefore, it would be possible that the high reactivity of the 
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aziridinium ring can compensate somewhat for any lowered muscarinic activity 
resulting from the steric hindrance due to the additional methylene group on 
the nitrogen. 
C. Preliminary Target Molecules 
The studies described above encouraged us to set our target molecules 
as shown in Fig. 10. The additional methyl group on aziridinium ring also was 
suggested to study the stereochemical environment of an anionic locus at the 
receptor site. Although, it was expected that maintaining the stereochemistry 
at the chiral center on the diastereoisomeric aziridinium compounds (33 - 36) 
would be difficult, it was a very interesting challenge to install the various 
stereocenters using different methodologies. 
AcO, ••• o 
N 
D 
31 32 
AcO,,,,,o 
N 
~CH 
3 
33 34 35 36 
Figure 10. Preliminary target molecules 
CHAPTER IV 
RESULTS AND DISCUSSION 
Summary: Synthesis of the precursors to target molecules (31-36) was 
explored by two different routes. First, we studied a synthetic pathway by way 
of the chiral 3-hydroxypiperidines, 43 and 70, which were synthesized from the 
optically pure enantiomers (S)-glutamic acid 37 and (R)-glutamic acid 64 
(Aldrich), respectively. We also used fractional recrystallization as a pivotal 
step toward the preparation of 31 - 36, using a chiral resolving agent to first 
separate the enantiomers of the 3-hydroxypiperidine from a commercially 
available racemic mixture (Fluka). This fractional recrystallization pathway 
was performed to assure that the enantioselectively synthesized chiral (S)- and 
(R)-3-hydroxypiperidines were enantioenriched without undergoing significant 
racemization during synthesis by comparing the physical properties of those 
piperidinols produced from each pathway. In section A, we will show how we 
approached to our target molecules by enantioselective synthetic strategy. In 
section B, we will describe the parallel route in which we used a fractional 
recrystallization method (Sievertsson et al., 1972; Lambrecht, 1976a,b). 
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A. Enantioselective Synthesis 
l. Preparation of (S)-(-)-3-Hydroxypiperidine 
Although several research groups have utilized fractional 
recrystallization of a racemic mixture of 3-hydroxypiperidine to access their 
chiral piperidine derivative compounds, few literature syntheses of (S)-(-)-3-
hydroxypiperidine 43 have been reported (Deane and Inch, 1969; Olsen et al., 
1985). In connection with our studies toward the synthesis of the possible 
chiral neurotoxins (31-36), which contain the 3-acetoxypiperidine unit with S 
or R configurations, we were interested in designing the synthetic pathway by 
way of constructing the key intermediate 43. We have succeeded in preparing 
(S)-(-)-(43) in six steps (Scheme II) in approximately 31 % overall yield from 
the commercially available, natural amino acid, (S)-(+)-glutamic acid 37. The 
individual steps of this synthesis are discussed next. 
Scheme II. Preparation of (S)-(-)-3-Hydroxypiperidine 
38 
O~··""'CB20Ta p-TsCl o~···""'cB2oB 
40 39 
l NaN3 / DMF, A 
41 
H2 (50 psi), Pd/C 
CH30H 
BOU 
N 0 
H 
42 
BOD 
N 
H 
43 
(S)-(-)-3-Hydroxypiperidine 
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In a typical diazotization procedure, (S)-( + )-glutamic acid 37 was treated 
with 2 M HCl aq. solution and sodium nitrite resulting in the crude lactone 
carboxylic acid (S)-( + )-(38) with retention of configuration. The procedure first 
results in the formation of a diazoyl group at C2, which lactonizes rapidly. The 
purification of (S)-( + )-(38) by single solvent (chloroform) crystallization afforded 
colorless, needle shaped crystals. However, the high yield (72 %) obtained by 
Doolittle's group (1984) was not obtained, and usually 40-60 % was isolated. 
In the familiar reaction of primary amines with nitrites and acid, the species 
that is acting as the effective nitrosating agent has been shown to depend on 
the conditions although it is apparently never HNO2 itself. At low acidity 
N2O3 (ONO-NO) is thought to be the predominant nitrosating reagent 
according the following equilibrium equation (Eq. 2): 
ONO-NO + H2 O (2) 
As the acidity increases, the protonated nitrous acid, H2O+-No and finally the 
nitrosonium ion +No are believed to be reasonable nitrosating agents along 
with nitrosyl chloride, NOCl when HCl is used as acid. The general 
mechanism of formation of diazonium salt can be described as shown in Fig. 
11. 
+ 
where X = ONO or H2o 
HOOC) .... ," + 
HOOC N=N 
+ 
H 
Figure 11. Formation of diazonium salt 
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I 
H 
Formation of the y-butyrolactone carboxylic acid (S)-( + )-(38) with 
retention of configuration can be interpreted by two possible mechanisms; 1) 
intramolecular participation by a-carboxylic group allows formation of an a-
lactone intermediate, which is subsequently ring opened by the nucleophilic y-
carboxylic moiety (Fig. 12), or 2) since the reaction was conducted in aqueous 
solution, water can first substitute the nitrogen leaving group and this 
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hydronium intermediate is then displaced by the y-carboxylic hydroxyl group 
(Fig. 13). 
(S)-diazoniu111 
H 
I (:OYO 
0~ 
+? 
H 
(R)-a-lactone 
intermediate 
(S)-y-butyrolacton• 
Figure 12. Formation of y-butyrolactone via a-lactone intermediate 
(S)-diazonium (R)-hydronium 
intermediate 
OYJ·""'COOB 
(S)-y-butyrolactone 
Figure 13. Formation of y-butyrolactone via hydronium intermediate 
Both mechanisms involve consecutive inversions of configuration resulting in 
retention of the original configuration. The lower yield possibly was caused by 
the interference of the acidic reaction conditions in which the relatively strong 
base, the primary amine group of glutamic acid, will be protonated leading to 
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reduced nucleophilicity. Taniguchi et al. (1974) converted this lactone 
carboxylic acid 38 to the corresponding lactone ethyl ester 44, and reported 
that the purification of this ester by vacuum distillation caused partial 
racemization at the high boiling point (Scheme III). 
Scheme III. Synthesis of (S)-(+)-y-Hydroxymethyl-y-butyrolactone 
O~·•"''COOB 
>90 % 
38 
O~··"'''co2Et + 
44 
a H+ / ethanol, benzene, A 
b 1) NaBH4 / ethanol 2) H3o+ 
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Surprisingly, they could reduce the lactone ethyl ester (S)-(+)-(44) to the 
primary carbinol (S)-(+)-(39) with NaBH4. NaBH4 is most known as a mild 
reducing reagent that is reluctant to reduce the ester group. Later, Ravid et 
al. (1978) studied this step more closely and found that the over-esterified side 
product (S)-(-)-(45) was produced along with the desired product 44, but they 
did not mention the ratio of these two products. Therefore, it is believed that 
the racemization mentioned by Taniguchi's group possibly resulted from 
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contamination by this over-esterified impurity 45 (see the sign of the rotation). 
Without further separation, both 44 and 45 were reduced together with N aBH4 
to yield (S)-(+)-(39). On the other hand, they found a more convenient direct 
reduction of the carboxylic acid 38 using borane-methyl sulfide to give high 
yields of 39 following distillation. The latter reagent was selected for our use, 
and (S)-( + )-y-hydroxymethyl-y-butyrolactone 39 was prepared in 90-92% yield 
following purification by flash column chromatography using 
methanol/chloroform ( 4:96) as the eluting system. 1 H and 13C NMR spectra 
of 39 were identical to the previous reports and the rotation was satisfactory. 
We also tried reduction of the lactone carboxylic acid with 1 M borane-
tetrahydrofuran complex in THF (Yoon et al., 1973). This stronger reducing 
agent, however, resulted in overreduction to afford an equilibrium of two 
lactols 46 and 47 which could be observed by TLC (stained with o-anisaldehyde 
with heating). 
46 
excess 
THF 
38 39 
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Consequently, lower yields of 39 were acquired using BH3 •THF complex in 
THF. The lactone alcohol 39 gave a Rr = 0.17 while lactol 46 (2-hydroxy-5-(S)-
hydroxymethyl tetrahydrofuran) showed a Rr = 0.09, and the 6-lactol 47 
showed a Rr = 0.20. Clearly, the chromatographic complexity further reduces 
interest in the use of this reducing agent. 
The tosylation (sulfonylation) of alcohols is a common transformation 
that is often used to facilitate subsequent nucleophilic substitution reactions. 
0 
+ c1-~-0-~ cH __ N__ a-l-o~-0-~ CH 
~I 
3 I o11 - 3 CH2c12 
Mori (1975) tosylated the lactone alcohol 39 withp-toluenesulfonyl chloride in 
pyridine (48 %), which was a general condition for tosylation of alcohols at that 
time. Ho and Davies (1983) modified and succeeded in obtaining the (S)-( + )-
tosylate 40 in higher yield (96 %) by using methylene chloride as solvent. 
Kabalka's group (1986) reported that the highest yields of pure tosylates based 
on starting alcohol (mostly primary alcohols) are obtained using a 1 : 1.5 : 2 
ratio of alcohol/tosyl chloride/pyridine in chloroform. They showed that 
pyridinium salts were generated in routine tosylation reactions in which 
pyridine is used as a base resulting in a concomitant loss of the desired 
tosylate product during workup. Olsen et al. (1985) modified the tosylation of 
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the lactone alcohol 39 by using a catalytic amount of N ,N-dimethylamino-
pyridine (94 % yield). Using Ho and Davies' method, we obtained tosylate 40 
(Scheme II) in comparable yield (93 %). The absence of hydroxyl group was 
recorded on IR and the two methylene protons are shown as an ABq pattern 
(4.13 ppm; ddd, J = 4.18, 8.69, and 11.0 Hz). 
Displacement of the sulfonate group with sodium azide in N,N-dimethyl-
formamide gave 5-azido-4-pentanolide 41 in 93 % yield. The N 3 stretching was 
recorded on IR (2120 cm-1) and this azide compound 41 shows very weak UV 
activity on TLC analysis. The transformation of 41 into (S)-(-)-3-
hydroxypiperidine 43 in two steps had been reported by Deane and Inch 
(1969). This report, however, contained no experimental details or yields. 
Olsen et al. (1985) described these steps in a somewhat advanced experimental 
section. The catalytic reduction of the lactone azide 41 generates the 
intermediate primary amine 48 (Fig. 14), which expands the size of the ring 
via intramolecular nucleophilic attack at the lactone carbonyl to form the 
powdery crystals of (S)-(-)-5-hydroxy-2-piperidinone 42 in 96 % yield (mp 120-
121 °C; lit. 121-122 °C). 
H2 , Pd/C o:ou 
N 0 
H 
41 48 42 
Figure 14. Ring expansion via primary amine 
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The new chiral center shows the same absolute configuration, but the sign of 
rotation of this lactam 42 changed from(+) to (-). 
Reduction of lactam carbonyl moieties had been reported by Corey's 
group (1975) using LiAlH4 (again, no experimental details or yields) and 
Olsen's group (1985) who utilized borane tetrahydrofuran complex. We tried 
to reproduce both methods but could not obtain a satisfactory yield of the 
piperidinol 43 (< 60 %). It is believed that the high solubility of the product 
3-hydroxypiperidine (43) in water (1 g / 10 mL) possibly caused low recovery 
during aqueous workup. The extremely highly polar amino alcohol 43 was 
purified by flash column chromatography using methanol/chloroform (3:7). 
Due to the use of high ratios of methanol as eluting solvent, some 
contamination of the product with silica gel resulted which caused broadening 
of 1H NMR peaks. Filtration through a Celite pad enhanced the purity of the 
compound, but significant loss of yield resulted. Only rotation value and 
melting point were reported in the literatures; however, the 1H NMR shows a 
spectrum consistent with the structure. 
Until racemic 3-hydroxypiperidine became commercially available, we 
had struggled to identify this highly polar compound 43 by TLC. To 
circumvent this problem, we imposed a high molecular weight protecting group 
on the hydroxyl group of the lactam 42 with or without a chromophore to aid 
visual detection on TLC and/or reduce the polarity of the desired product 43. 
Silane reagents such as tert-butyldimethylsilyl chloride (TBDMSCl), 
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HOD 
N 0 
imidazole, DMF 
H 
42 
diphenylmethylsilyl chloride (DPMSCI), and trimethylsilyl chloride (TMSCl) 
were used to protect the hydroxyl group on the lactam 42. 
The methyl groups attached to the silane appeared at 0.1 ppm and, except the 
TMSCl protection, strong UV activities induced by the phenyl groups were 
detected on TLC analysis. Reduction of the cyclic amide group was next 
attempted with BH3 •THF reagent. However, it was found that the borane 
also removed the protecting group as well as reducing the amide function, 
which led back to 43. Thus, a significant portion of our investigation became 
dedicated to finding a protecting group strategy that would nearly furnish the 
target precusors. 
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2. Synthesis of(S)-(-)-3-Acetoxypiperidine-ADivergent Intermediate 
Molecule 
After the key intermediate 43 was synthesized, studies were continued 
to obtain the divergent molecule (S)-(-)-3-acetoxypiperidine 51. With 51 in 
hand, an array of aziridinium precursor functional group could be installed. 
First, we simply tried the direct approach; acetylate the hydroxyl function with 
acetic anhydride and pyridine in the presence of catalytic amount of N,N-
dimethylaminopyridine (Scheme IV). 
Scheme IV. Acetylation of (S)-(-)-3-Hydroxypiperidine 
BOD Ac2o AcOD + BOD + AcOD 
DMAP, pyr 
N N N N 
H H I I 
Ac Ac 
43 51 52 53 
However, although the desired product, 0-acetylated 51, was obtained, the 
expected competition between the hydroxyl group and the cyclic secondary 
amine resulted to give N-acetylated 52, and diacetylated 53 side products 
which were recorded on 1 H NMR by showing two different chiral protons at C3. 
The chiral proton of 52 is shown at the similar region to the proton of 3-
hydroxypiperidine 43 (3.6-3. 7 ppm) while the chiral protons of 51 and 53 are 
shown at further downfield (4.9-5.0 ppm). In an attempt to reduce reaction at 
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the secondary amine, the acetylation was conducted under acidic conditions 
with the expectation that protonation at the amine would first occur thereby 
reducing its reactivity. Despite all attempts with acid conditions, mixtures of 
acetylated products were obtained. To circumvent this problem with the amine 
moiety, we protected the amine function using carbobenzyloxy chloride (Cbz-Cl) 
(Scheme V). 
Scheme V. Synthesis of (S)-3-Acetoxypiperidine via Protecting Amine Moiety 
43 54 55 51 
a; Cbz-Cl / NaHC03 , toluene b; Ac2o / DMAP, pyridine c; H2 (35 psi), Pd/C, CH30H 
The protecting studies were performed first with commercially available 
racemic 3-hydroxypiperidine (Fluka), and gave an outstanding yield (90-95 %). 
Similar results were achieved with the chiral (S)-(-)-hydroxypiperidine 43 to 
yield 54 (~90 %). An 1H NMR study of this amine-protected intermediate 54 
showed a very poorly resolved spectrum, and it is believed that this poor 
resolution resulted from equilibration of the highly flexible protecting group. 
However, removal of the Cbz group yielded (S)-(-)-(43) which indicates the 
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protecting process was successful. Taking advantage of the successful result 
from the protecting study, in order to prevent significant loss of 43 during the 
purification process, we conducted the following two steps, namely, the 
reduction of lactam and the amine protection, in situ without further 
purification of 43. The overall yield of 54 from the lactam 42 was 76%, which 
implies that, considering the yield of protecting step (90 % ), we recovered more 
than 80 % of 43 without significant loss (after purification, the yield of 43 was 
< 60 %, and this chiral piperidinol was contaminated by silica gel). Conversion 
of the hydroxyl group (Scheme V, step b) to acetoxy compound 55 was now 
achieved successfully (85 %) using acetic anhydride, pyridine and a catalytic 
amount of DMAP under anhydrous conditions. Again, resolution of the 1 H 
NMR was extremely poor due to the flexibility of the protecting group; 
however, a successful elemental analysis result indicates that acetylation 
proceeded. 
The removal of Cbz group (Scheme V, step c) was conducted under 
balloon pressure. Unfortunately, it was found that the free base 51 was 
somewhat unstable forming either the N-oxide, and/or underwent 
transacetylation (Fig. 15) resulting in N-acetyl-3-hydroxypiperidine. This 
latter side reaction predominates after long hydrogenolysis reaction times 
(usually, stirring overnight under balloon pressure). Therefore, in order to 
shorten the period of reaction time, we performed this step on a Parr 
Hydrogenator, using 10 % palladium on active carbon as a catalyst, under 35 
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Figure 15. Transacetylation between two (S)-(-)-3-acetoxypiperidines 
psi (slightly higher than 1 atm) of hydrogen with which the reaction completed 
within three hours (monitored by TLC). Purification of 51 was achieved by 
flash column chromatography using chloroform/methanol (9: 1) as eluting 
system to yield a pale yellow liquid 51. The free base, secondary amine proton 
appears at 7. 96 ppm as a singlet, and removal of the Cbz group shows a better 
resolved spectrum. 
In Chapter III, it was described that Lambrecht and Muschler 
synthesized and investigated the muscarinic activities of N-methyl-3-aceto:xy-
piperidine 23 and N,N-dimethyl-3-aceto:xypiperidinium iodide 21. In their 
synthetic method, alkylation of the amine was achieved first by reacting the 
chiral 3-hydro:xypiperidine with methyl iodide, and later, esterification was 
managed on the hydroxyl group as shown in Scheme VI. 
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Scheme VI. Synthesis of (S)-N-Methyl-3-acetoxypiperidine and (S)-N,N-
Dimethyl-3-acetoxypiperidinium Iodide 
BOD CH3 I BOD + BOD 
H H .,,.a, r 
H I H3C CH3 
CH3 
43 56 57 l Ao,o l Ac,o 
AcOD AcOD 
H .,,.a, r 
I H3C CH3 
CH3 
23 21 
During construction of the f3-hydroxyalkyl-piperidine derivatives, we 
recognized that conducting the alkylation before esterification would cause 
difficulties in controlling selective esterification on the hydroxyl group of the 
piperidine ring while the other hydroxyl group on the N-alkyl chain must 
remain unreacted in preparation for the next step (chlorination). Hanin's 
group managed a very similar step by stopping the acetylation at the point the 
diacetylated product began to form (Chapter III, Scheme I). However, low 
yields were reported. Therefore, in conclusion, it was a very advantageous idea 
that we prepared the divergent intermediate 51 via protecting the amine group 
with Cbz-Cl, since selective functionalization of one hydroxyl group at a time 
was managed. 
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3. Alkylation of (S)-(-)-3-Acetoxypiperidine and Synthesis of f3-
Chloroalkyl-3-acetoxypiperidines 
Several alkylating reagents were planned to react with the divergent 
intermediate 51 to eventually obtain the N-(f3-chloroalky)piperidines, the 
precursors of our aziridinium target molecules (Scheme VII). 
Scheme VII. Synthesis of N -(f3-Chloroalkyl)-(3S)-acetoxypiperidines 
CH3I ... D 
CH30H 
.,....a,r 
H3C CH3 
21 
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CH30H CH2Cl2 H H 
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L__ .. ·u AcOD H H CH3 SOC12 51 CH30H H CH2Cl 2 H 
YOH l.......yc1 
CH3 CH3 
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CH3 CH3 
60 63 
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Methylation of (S)-(-)-(51) with methyl iodide was sucessfully achieved 
to yield (S)-(-)-N ,N-dimethyl-3-acetoxypiperidinium iodide 21 (65 % ). An excess 
amount of methyl iodide was used to ensure that the reaction was completed 
without leaving any monoalkylated product 23. An 1 H NMR study indicated 
that the two methyl groups on the nitrogen are not located in the same 
chemical environment (Fig. 16) showing two methyl peaks with a 0.05 ppm 
difference at chemical shifts 3.50 and 3.55 ppm. However, the chemical shift 
difference is not very large, possibly indicating that the 1,3-diaxial interaction 
between N-methyl and acetoxy groups is not significant or ring flip leads to a 
time averaged equilibrium. This reduced interaction results from the fact that 
the acetoxy moiety may assume a conformation pointed away from the N-
methyl group. 
H 
H 
Figure 16. Two different environments for methyl groups of the N,N-dimethyl-3-
acetoxypiperidine 21. The -CHg(a) shows interaction with the axial acetoxy group appeared 
at slightly further down field (3.55 pvm), while the -CHg(b) is away from the acetoxy group 
resulted in upper field (3.50 ppm) in H NMR spectrum. 
Synthesis of the (S)-(-)-N-(2-hydroxyethyl)-3-acetoxypiperidine 58 was 
approached by a variety of methods as shown in Table XI. First, reaction with 
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Table XI. Reagents and yields used for synthesis of (S)-(-)-N-(2-
hydroxyethyl)-3-acetoxypiperidine 58. 
Reagent 
0 )l 
0 0 
\_J 
ethylene carbonate 
Cl ------Br 
1-bromo-2-chloroethane 
Cl --------OH 
2-chloroethyl alcohol 
Br -------OH 
2-bromoethyl alcohol 
Reaction condition 
DMF 
Nal/THF 
a : yielded N-(2-chloroethyl)-3-acetoxypiperidine 
Yield 
no reaction 
~ 10% 
23%a 
a, b 
15.5 % (77.5 %) 
< 10% 
11.4 % 
40.6% 
18% 
38% 
b : 77 .5 % yield was calculated based on the amount of consumed starting material, 
about 80 % of unreacted starting material was recovered. 
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2-haloethyl alcohols were studied for this alkylation step. However, the yield 
of reaction of 51 with 2-bromo- or 2-chloroethyl alcohol in DMF, H 20, or THF 
was not satisfactory (-20 %). Unfortunately, reaction of 51 with ethylene 
carbonate in anhydrous methanol did not show evidence of alkylation; however, 
some reaction proceeded in the presence of potassium carbonate. 
Testing the reactivity of this cyclic secondary amine 51 with epoxides 
was initiated by using a racemic mixture of propylene oxide. Even though 
separation of the diastereoisomers seemed to be impossible (overlapping spots 
of the two diastereoisomers on TLC), the yield of this reaction in H20 or 
methanol showed remarkable enhancement. Therefore, before the 
commercially available ethylene oxide (Fluka) was purchased, we tried to first 
generate the ethylene oxide in situ by stirring 1 : 1 equivalent amount of 2-
bromoethyl alcohol and sodium hydroxide in water at 0 °C and manage the 
alkylation with 51 in aqueous media. Problems arose in isolation due to 
increased solubility of the primary alcohol 58 in the aqueous reaction mixture. 
After removal of most of the water under reduced pressure, the concentrated 
residue was chilled at - 78 °C. Using a vacuum pump, the frozen, last trace of 
water could be removed taking advantage of low heat of sublimation of ice 
(freeze drying) under a extremely low pressure, to give a yellow colored liquid 
residue which was diluted with ethyl acetate followed by drying over Na2SO 4. 
Purification by column chromatography afforded the pure alcohol 58 with 
somewhat low yield (mostly 35 - 40 %). Two sets of methylene protons of N-
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alkyl moiety was shown at 2.47-2.51 and 3.53-3.56 ppm as triplets on the 1H 
NMR. The low yield might have been caused by the uncertain amount of the 
ethylene oxide produced in situ, or the oxirane molecules were polymerized 
under the basic aqueous conditions. It also could be possible that while the 
last trace of water was being removed under vacuum pump pressure, the protic 
solvent molecule could carry the product or this alcohol product could be 
evaporated coincidently. 
The direct use of commercially available ethylene oxide still did not 
afford a reasonable yield when the reaction was conducted in water as the 
reaction solvent system. Changing the solvent to methanol gave very 
consistent results with much higher yield(~ 60 %) due to the simple workup. 
The reaction had to be stopped before complete consumption of the starting 
material because the produced tertiary amine can be over-alkylated to yield 
bis-(2-hydroxyethyl)-3-acetoxypiperidinium (below). 
51 
0 
excess D AcOD 
fRl 
HO OH 
Sla 
bis-(2-hydroxyethyl)-3-acetoxypiperidinium 
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To avoid ovrealkylation, oxirane gas was effused into the stirring solution of 
(51) in methanol at ice-bath temperature, then the ice bath was removed. 
Generally, the formation of the overalkylated product was detected when the 
reaction was stirred for more than 1.5 h after effusion of ethylene oxide. 
Regioselective alkylation of 51 with chiral (S)-(-)- or (R)-(+)-propylene 
oxide (Fluka) afforded similar results to yield the diastereoisomers, (S,S)-( + )-N-
(2-hydroxypropyl)-3-acetoxypiperidine 59 and (R,S)-(-)-N-(2-hydroxypropyl)-3-
acetoxypiperidine, respectively 60, when the reactions was stirred at 5 °C 
overnight (Fig. 17). The newly generated chiral protons of the side chain 
appeared at 3. 72-3.81 ppm region as a multiplet. As a doublet peak, the -CH3 
group of (S,S)-isomer shows a somewhat smaller coupling constant (6.2 Hz) 
than that of (R,S)-isomer (8.3 Hz). 
AcO~ 
~) -~ 
:~ce, 
.. 
b *:anew chiral center OH 
a (major) b (minor) 
Figure 17. Regioselective nucleophilic substitution on a unsymmetric epoxide. The cyclic 
secondary amine will attack the propylene oxide at the carbon which has less steric hindrance 
(route a) preferentially with a 96 : 4 of ratio. 
(S,S)-( + )-(59) and (R,S)-(-)-(60) are less reactive toward overalkylation 
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than 58, probably, due to the increased steric hindrance of the secondary 
alcohol chain of the product, and the propylene oxides, so formation. of the 
overalkylated quaternary ammonium was inconsequential. The chiral (3-proton 
on the ethyl chain, which is located next to the hydroxyl group, was detected 
at 3. 72 - 3.80 ppm as a multiplet peak on the 1 H NMR spectrum while the 13-
methylene protons next to the hydroxyl group of the primary alcohol 58 were 
shown at 3.53 - 3.56 ppm as a triplet. 
Syntheses of the asymmetric mustard molecules (61 - 63), which are 
precursor molecules of the aziridinium ions, were achieved by reacting the 
alcohols (58 - 60) with freshly distilled thionyl chloride (over rinsed oil) in 
methylene chloride at low temperature under argon atmosphere. These (3-
chloroethyl (or propyl) amines (61 - 63) were obtained as their hydrochloride 
salts to prevent immediate further reaction including dimerization or, possibly, 
aziridinium formation. The hydrochloride salt could be converted to the free 
base by stirring in diethyl ether or methylene chloride with sodium 
bicarbonate, followed by flash column chromatography using petroleum ether 
and diethyl ether (1:1 or 2:1) to afford the j3-chloroethyl (or propyl) amines as 
pale yellow liquids. 
For the primary chloride compound 61, the j3-methylene protons next to 
the chloride appeared at 3.51 - 3.56 ppm in the 1 H NMR spectrum showing 
virtually no change in chemical shift compared to the precursor (3-hydroxy 
molecule 58 (3.53 - 3.56 ppm). However, the a-methylene protons' chemical 
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shift did change from 2.47 - 2.51 ppm to 2.70 - 2.75 ppm upon conversion from 
alcohol to chloride. For the secondary chloride compounds 62 and 63, the 
chemical shift of the chiral f3-proton changed from 3.72 - 3.80 ppm to 3.95 -4.06 
ppm. The doublet of the terminal methyl group of the propyl chain also 
showed a significant change in chemical shift from 1.08 ppm to 1.47 ppm 
proving that the mustard compounds were successfully synthesized. The use 
of thionyl chloride in the presence of a base, such as pyridine or TEA, inverts 
the configuration of the chiral center on the alkyl chain. As mentioned earlier, 
this chlorination was managed without using base control which will allow this 
step to proceed with retention of configuration via SJi, mechanism. This 
reaction has been interpreted mechanistically as follows: 
R 
R' ...._-.c-oH 
I 
R" 
1 
+ SOC1 2 ---
R_ 0 R 
R' ....:
1
··c .t'~, ..... ,i' = O __ 2 ___ R' " 
...._c-c1 + so2 I 
R" Cl R" 
intermediate 
No change in configuration can take place in stage 1 as the C-O bond is not 
broken. In the second stage, where this bond is broken, attack by Cl takes 
place from the same side of the carbon atom because of the orientation of the 
intermediate (Sykes, 1970). 
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4. Synthesis of (R)-3-Acetoxypiperidine Derivatives 
This enantiomer of (S)-3-acetoxypiperidine and its derivatives were 
prepared from (R)-(-)-glutamic acid 64. The sequence is analogous to Scheme 
II as shown in Scheme VIII and Scheme IX. 
Scheme VIII. Synthesis of (R)-( + )-3-Acetoxypiperidine 
,,, ... lCOOH 
H2R
1 COOH 
64 
O~CH2R3 
68 
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Scheme IX. Synthesis of N-((3-Chloroalkyl)-(3R)-acetoxypiperidines 
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As expected, unlike the natural S-(+)-glutamic acid 37, the unnatural R-
(-)-glutamic acid 64 is much more expensive starting material. Therefore, 
before we began the synthesis of enantiomer series of mustard compounds (74 
and 78 - 80) from the (R)-(-)-glutamic acid 64, we first attempted to invert the 
configuration of the C3 of the (S)-(+)-N-Cbz-3-hydroxypiperidine 54, which is 
obtained from the relatively inexpensive natural amino acid 37. 
Using trifluoroacetic anhydride, transformation of the hydroxyl group of 
54 into an excellent leaving group, trifluoroacetate, was attempted in the 
presence of pyridine as base in N,N-dimethylformamide with the hope that the 
trifluoracetate would be exchanged with acetate anion to obtain (R)-(+)-N-Cbz-
3-acetoxypiperidine 71, the enantiomer of 54 (Scheme X). However, as 
illustrated in Scheme X, pyridine first displaced the trifluoroacetate group 
forming a pyridinium intermediate before the acetate anion was added 
resulting in partial racemization of configuration. The acetate seemed not 
strong enough to exchange this pyridinium even at high temperature (~80 °C). 
More hindered base such as triethyl amine and better leaving groups (e.g., 
triflate, etc.) would be an ideal choice for this reaction, but further study of 
this system was not explored. 
Scheme X. Inversion of Configuration Using Trifluoroacetic Anhydride. 
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I 
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II CF3COD NaOAc 
N 
I 
Cbz 
trifluoroacetate interlllediate 
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Ot .. 0 NaOAc 
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I 
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The conversion of chiral alcohol into a chiral acetate with inversion of 
configuration using diethyl azodicarboxylate (DEAD) and triphenylphosphine 
was reported by Mitsunobu (1981). In Scheme XI, the mechanism of this 
reaction with (S)-(+)-N-Cbz-3-hydroxypiperidine 54 is illustrated. 
Scheme XI. Inversion of Configuration Using Mitsunobu Conditions 
0 0 
II II 
Eto-c-N=N-c-oEt 
0 0 
II B II 
Eto-c-N-N-c-oEt 
H 
+ 
+ 
0 0 
II - •I 
Eto-C -N-N ~'c -oEt 
I Ph p+ 3 
0 0 
II H II 
Eto-c -N-N-c -OEt 
Aco,,,,,,_Q 
N 
I 
Cbz 
Ph3!+ AcO-
+ 
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An equivalent amount of glacial acetic acid and 1.27 equivalents of 
triphenylphosphine and DEAD were reacted with 54 in THF, however, we 
could not achieve a satisfactory result(< 20%). 
Having difficulties in inverting configuration at C3 position and 
experiencing that this "quick way" was not easy to achieve, the author had to 
go back to our original strategy to obtain (R)-( + )-3-hydroxypiperidine in which 
the entire synthesis had to begin from the unnatural amino acid, (R)-(-)-
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glutamic acid. However, we expected that providing enough amount of (S)-(-)-
and (R)-( + )-3-hydroxypiperidines by fractional recrystallization method would 
compensate this time depleting synthetic strategy. 
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B. Fractional Recrystallization of Chiral 3-Hydro:xypiperidine 
1. Preparation of 4-Chlorotartranilic Acid -A Chiral Resolving Agent 
Tartranilic acids are well known as exceptionally useful resolving agents 
for racemic bases. As illustrated in Scheme XII, ( + )-4-chlorotartranilic acid 85 
was prepared by reaction of 4-chloroaniline with ( + )-diacetoxysuccinic 
anhydride 83 followed by basic hydrolysis of the acetyl groups first described 
in the procedure of Pressman et al. (1948). The same procedure worked fairly 
well with (-)-diacetoxysuccinic anhydride 84 to give (-)-4-chlorotartranilic acid 
86. The ( + )- and (-)-diacetoxysuccinic anhydrides were readily prepared from 
the tartaric acids, (+)-(81) and (-)-(82), respectively (Rabjohn, 1963). 
Scheme XII. Synthesis of Chiral 4-Chlorotartranilic Acid 
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(+)-Tartaric acid 81 has the 2R: 3R absolute configuration while (-)-tartaric 
acid 82 shows 2S : 3S configurations. Therefore, ( + )-4-chlorotartranilic acid 85 
will have 2R: 3R configuration and (-)-isomer 86 will maintain its own 2S: 3S 
configuration. 
The diacetoxysuccinic anhydrides are not stable so they were prepared 
only as needed and converted directly to the anilide. Two acetoxy methyl 
groups are shown at 2.21 ppm in 1H NMR spectrum while the succinic 
anhydride chiral protons are shown at 5.67 ppm. Both chiral resolving 
compounds, 85 and 86, were recrystallized from absolute ethanol and water at 
5 °C to yield colorless, needle shaped crystals (mp 192 -194 °C; lit. 193 - 195 
oc). 
2. Fractional Recrystallization 
The mechanism of formation of the diastereomeric salt of a chiral 3-
hydroxypiperidine with the chiral resolving agent could be interpreted by the 
physical/structural interactions between two chiral molecules. It is thought 
that, in terms of spatial arrangement, the hydroxyl groups of the chiral ( + )-4-
chlorotartranilic acid would interact (or repulse) with the hydroxyl group of the 
unfavored chiral enantiomer of 3-hydroxypiperidine ((-)-isomer). Hydrogen 
bonding between two molecules also could be considered as an important 
factor. Therefore, this physical/structural interaction results in exclusive 
formation of (+)-(+)-salt. With the same reason (-)-4-chlorotartranilic acid will 
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form a diastereomeric (-)-(-)-salt only. From a slow recrystallization at room 
temperature (Sievertsson, 1972), 60 - 70 % of the diastereomeric salts (needle 
shape) were recovered (Scheme XIII). Treatment with ~CO3 or NaHCO3 
resulted in dissociation of the acid and base to yield the chiral 3-
hydroxypiperidines (pale yellowish needles, 56 - 62 %). 
Scheme XIII. Fractional Recrystallization of the Racemic Mixture of 
3-Hydroxypiperidine Using Chiral 4-Chlorotartranilic Acid 
(racemic mixture) 
(+)-4-chlorotartranilic acid (-)-4-chlorotartranilic acid 
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3. Comparison of the Physical Properties of the 3-Hydroxypiperidines 
Obtained by the Enantioselective Synthesis and Fractional 
Recrystallization Methods 
1 H and 13C NMR spectra of the chiral 3-hydroxypiperidines were 
important first determinants in the structure conformation. The other physical 
properties are compared as shown in Table XII. 
Table XII. Physical properties of chiral 3-hydroxypiperidines from 
enantioselective synthesis and fractional recrystallization. 
synthetic pathway content crystallization 
56 - 61 mp (°C) 56 - 60 
- 8.94 (c 4.7, CH30H) [a]D 24 (o)a - 8.01 (c 1.32, CH30H) 
+ 10.45 (c, 1.0, CH30H) [a]D24 (°)b + 9.45 (c 0.65, CH30H) 
a: (S )-(-)-3-hydroxypiperidine, b: (R)-( + )-3-hydroxypiperidine 
Although the rotation values slightly deviate from each other, depending on 
the concentration of the samples, it is reasonable that the enantiomers of 3-
hydroxypiperidines obtained from the fractional recrystallization method are 
optically pure and compare with the results from the enantioselective synthetic 
pathway. 
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4. Convergent Approach 
The fractional recrystallization method was very useful for two reasons; 
to shorten the period of time to aquire material because a large scale process 
was being contemplated and moreover, fractional recrystallization is relatively 
inexpensive. In order to access enough of the mustard compounds (61 - 63 and 
78 - 80) for biological evaluation, the synthesis was resumed after chiral 3-
hydroxypiperidines were obtained from fractional recrystallization. However, 
the neutralization of each diastereomeric salts yielded a poor recovery of 3-
hydroxypiperidines (usually less than 60 %), therefore, a solution of Cbz-Cl in 
toluene was added directly to the solution of salts during free-basing with 
~CO3 or NaHCO3. After purification by flash column chromatography, the 
yield of N-Cbz-3-hydroxypiperidines was up to 84. 7 %, which means that the 
recovery of the chiral 3-hydroxypiperidines was higher than 90 %. 
Acetylation, hydrogenolysis, alkylation, and chlorination were conducted 
following the procedures described in section A to obtained those mustard 
compounds (61 - 63 and 78 - 80). 
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C. Formation of a Representative Aziridinium Ion 
1. Making an Ion Pair of Aziridinium Cation with a Mild We_akly 
Nucleophilic Anion 
The first postulate of the existence of an ethylenimonium or aziridinium 
compound was given by Marckwald and Frobenius (1901) from the product 
resulting from treatment of l-j3-chloroethylpiperidine hydrochloride with 
limited base. It is believed that, considering the reaction condition and the 
purification method, the product Marckwald and Frobenius obtained was a bis-
piperidinium salt as more reasonable. Skinner et al. (1961) and Hennion and 
Butler (1962) showed that some of aziridine hydrochloride could be isolated. 
However, these hydrochloride salts were prepared from relatively stable 
tertiary amines by addition of ethereal hydrogen chloride. A series of studies 
of the synthesis of small charged rings have been reported by Leonard's group 
(1960, 1962, 1963a,b, 1964, 1965a,b). Since the charged three-membered ring 
was known to open readily in the presence of most anions, including halides, 
making an ion pair of aziridinium cation with a very weakly nucleophilic 
anions such as perchlorate and fluoroborate was guided (Leonard, 1962). 
Bartlett et al. (1949) found that j3-diethylaminoethyl chloride 88 dimerizes 
readily in 2:1 acetone-water to give 1,1,4,4-tetraethylpiperazinium dichloride 
90 (Scheme XIV). Therefore, anhydrous reaction condition must be used in 
order to prevent obtaining the dimeric aziridinium salt. 
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Scheme XIV. Dimerization of j3-Diethylaminoethyl Chloride 
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Leonard's group (1965) showed a direct comparison of the "monomeric" and 
"dimeric" structures of aziridinium salts resulting from N-j3-chloro-
ethylpiperidine using NMR and other analytical data (Scheme XV). 
Scheme XV. Formation of Monomeric and Dimeric Aziridinium Salts from 
N-j3-Chloroethylpiperidine 
C;9_ 
4 
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2. Detection of Spirocyclic Aziridinium Cation via NMR 
As illustrated in Scheme XV, the "monomeric" aziridinium, 3-azonia-
spiro[2.5]octane perchlorate 92, shows a great similarity in molecular structure 
to our target molecules (31, 32, and 33-36). Therefore, study was continued 
by treatment of (S)-N-(2-chloroethyl)-3-acetoxypiperidine 61 with silver 
perchlorate in an anhydrous solvent such as acetone, 2-butanone, or methylene 
chloride. The former two solvent systems showed much faster progress in 
reaction than a methylene chloride system. After innumerable trials of 
purifications, we could obtain (S)-5-acetoxy-3-azoniaspiro[2.5]octane 
perchlorate 31, and succeeded in obtaining an 1H NMR spectrum (Fig 19d). 
The mustard ring protons appear as broad quartets or, possibly, a doublet of 
quartets at 3.18 ppm. Fig. 18 illustrates the chemical shifts and reasonable 
multiplicities of the protons of the aziridinium 31. The low melting point 
convinced us to believe that we obtained a "monomeric" aziridinium cation. 
2.13 (s) 
<•> X, ( 3.18 (ddd) 
1.85-1.97 
+ ,,,18 H .•' 
B 
B 
<•>\__ B 3.88-3.95 (dd) 1.98-2 .04 B 
5.21-5.26 (m.) 
'-.__3.69-3.71 (tbr) 
Figure 18. The chemical shifts (ppm) and mutiplicities of the protons of (S)-5-acetoxy-3-
azoniaspiro[2.5]octane perchlorate 31. 
89 
Reproduction of this aziridinium was not easy to achieve. However, formation 
of the aziridinium moiety was also detected by time dependent 1 H NMR study 
(Fig. 19a-d). 
/ 
, .. ,.0 ... 3.0 2.5 2.0 1.5 PPH 
Figure 19a 0 min; 1H NMR of (S)-N-(2-chloroethyl)-3-acetoxypiperidine. 
2.0 l.5 PPM 
Figure 19b. 15 min after addition of silver perchlorate; The typical quartet peak of the 
aziridinium cation is about to form (3.10-3.20 ppm). The two triplets from starting material 
is begun to broaden. 
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Figure 19c. 1 hour later; the quartet of the ethylenimonium moiety is now shown relatively 
clearly. The chemical shift of the chiral proton (C5) is being relocated at further downfield due 
to the formation of positive charge on the nitrogen. 
. , ,.., t 
., .. ~1_.,l 
", } . . I (' l 
~~_,.,______t ~ 
···'i:'.;~--1 .... :..!·,• 
Figure 19d. 1H NMR of the (S)-5-acetoxy-3-azaniospiro[2.5]octane perchlorate (after 
purification). 
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Several other conditions were studied to form the aziridinium moiety. 
Refluxing the primary chloride precursor compounds (61 and 78) in benzene, 
in the hope of seeing precipitation of aziridinium salt. However, even more 
than 72 hours of reflux did not show any advance in the reaction. Acetonitrile 
or DMF solvent systems also did not afford our desired aziridiniums. 
Triethylamine was added in DMF to generate basic conditions and stirred with 
neat heating or refluxed, but the same result was observed. 
Theoretically, forcing a secondary chloride to undergo a substitution via 
~2 mechanism could be achieved by choosing a solvent system with a highly 
polar aprotic nature such as DMF, DMSO, or acetone. To avoid sophisticated 
workup, we first treated the secondary chloro-compounds (62/63 and 79/80) 
with silver perchlorate in anhydrous acetone. However, the crude products 
were not easy to crystallize. 1H NMR study indicated that the aziridinium 
cations, 5-acetoxy-2-methyl-3-azoniaspiro[2.5]octane perchlorates (33-36) were 
formed, but racemization also occurred showing two doublets for the methyl 
group on the C2 position. 
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D. Future work 
Enantioselective synthesis of (S)-5-acetoxy-3-azoniaspiro[2.5]octane 
aziridinium ion 31 has been achieved, and all the reaction conditions and 
strategies to reach this final stage are optimized. Making the enantiomer of 
31 would not be that difficult, however, more study would be required to find 
better or easier workup method. For the secondary chloro compounds, 
exploring the proper solvent systems will be the only task. The author believes 
that these spirocyclic aziridinium ions will show certain level of potency toward 
the muscarinic receptor, and related biologically active targets. The precursor 
mustard molecules (chloride compounds) are to be tested for their muscarinic 
potencies as well. The half-life of this new series of aziridiniums will be 
studied in the air or in buffer solutions of different pH's. 
Finally, as mentioned in Chapter II, development of prodrug delivery 
systems by attaching a certain length of hydrocarbon chain is to be explored 
with strategy of modification of carbonyl moieties of the lactams (42 and 69). 
CHAPTERV 
EXPERIMENTAL SECTION 
General methods. Commercially available reagents were purchased from 
Aldrich Chemical Co., Milwaukee, Wisconsin, and Fluka Chemical Corp., 
Ronkonkoma, New York. All solvents and reagents were purified when 
necessary by standard literature methods (Perrin, 1980). Melting points were 
determined on a Fisher-Johns melting point apparatus and are uncorrected. 
Analytical thin-layer chromatography (TLC) was conducted on E. Merck 
aluminum-backed, 0.2 mm silica gel 60F254, TLC plates. Visualization was 
affected with an ultraviolet lamp and/or anisaldehyde stain (2% solution of o-
anisaldehyde in 95:4:1 absolute ethanol-concentrated sulfuric acid-glacial acetic 
acid), PMA (phosphomolybdic acid in ethanol), or ninhydrin (5% in ethanol) 
with heating. Flash chromatography was performed with Kieselgel 60, 230-400 
mesh (Merck). Elemental analyses were performed by Midwest Microlab Ltd., 
Indianapolis, Indiana. 
Proton(1H), Carbon (13C) NMR spectra were recorded on a Varian VXR 
300-MHz instrument in deuterated chloroform (CDC13) unless specified 
otherwise. Pertinent proton frequencies are tabulated in the following order: 
chemical shift (b in ppm), multiplicity (s, singlet; d, doublet; t, triplet; q, 
quartet; m, multiplet), coupling constant (J in Hertz), and the number of 
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hydrogens. Proton and carbon frequencies of spectra obtained are relative to 
chloroform (1H, 7.24 ppm; 13C, 77.0 ppm) as an internal standard. unless 
specified otherwise. 
Infrared data (IR; CDC13) were obtained on a Perkin-Elmer Model 1310 
instrument. Salient IR features were tabulated in decreasing wavenumber 
(cm-1). Gas chromatography analyses were performed on a Hewlett-Packard 
Model 5890 (DB-1 column; range, 50-250 °C; rate, 20 °C/min) and Integrator 
Model 3392A. Rotation of each molecule was recorded on Perkin-Elmer Model 
241 Polarimeter (Na lamp) at room temperature in appropriate solvents (c = 
100 x g/mL). 
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Part I. Enantioselective Synthesis 
1. (SJ-( +)-5-0xo-2-tetrahydrofurancarboxylic acid 38 
(S)-( + )-glutamic acid 37 (29.9 g, 0.2 mol) was stirred in 4M HCl aq. (130 
mL) at ice bath temperature. A solution of N aNO2 (20. 7 g, 0.3 mol) in H2O ( 45 
mL) was added dropwise for a period time of 20 min. Stirring overnight at 
room temperature resulted in a clear solution and removal of water under 
reduced pressure yielded white oily solid residue. The residue was shaken 
with hot acetone (300 mL) and filtered. The insoluble material was washed 
with additional hot acetone (100 mL). The filtrate and washings were 
combined. Removal of acetone gave a pale yellow syrup (23.67 g, 91 %) which 
showed similar NMR spectra (for both 1H and 13C) to the purified product. 
The last trace of acetone was removed in vacuo, and the viscous residue was 
solidified after addition of a few seed crystals. The solid was dissolved in 
portions of hot chloroform (500 mL) and stirred over Na2SO 4 at ~ 60 °C for 3 
hr (most of oil present was captured by N¾SO4). The drying agent was 
filtered and the volume of chloroform solution was reduced to about 200 mL 
by rotary evaporation. A few seed crystals were added and the solution was 
chilled at -30 °C. White crystals were obtained (17. 7 g, 68.0%) (Mori, 1975; 
Doolittle and Heath, 1984; Olsen et al., 1985): [a]D24 = +14.8° (c 2.3, CH3OH); 
mp 70-72 °C; 1H NMR o 2.32-2.42 (m, lH), 2.52-2.68 (m, 3H), 4.95 (dd, J = 4.2, 
8.4 Hz, lH), 11.48 (s, lH); 13C NMR o 25.7, 26.7, 75.2, 174.7, 176.5. 
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2. (R)-(-)-5-Oxo-2-tetrahydrofurancarboxylic acid 65 
Obtained from (R)-(-)-glutamic acid 64: [aJn24 = -13.8° (c 5.0, CH3OH); 
mp 70-72 °C; 1H NMR b 2.32-2.42 (m, lH), 2.52-2.68 (m, 3H), 4.95 (dd. J = 4.2, 
8.4 Hz, lH), 11.48 (s, lH); 13C NMR b 25.7, 26.7, 75.2, 174.7, 176.5. 
3. (SJ-(+ )-y-Hydroxymethyl-y-butyrolactone 39 
The lactone carboxylic acid 38 (15.64 g, 0.12 mol) was dissolved in dry 
THF (80 mL) and stirred for 20 min at -78 °C under argon atmosphere. 2 M 
borane-methylsulfide in THF (65 mL, 0.13 mol) was injected, warmed up to 
room temperature, and stirred for 14 hr. The completion of the reaction was 
monitored by TLC and the mixture was quenched by cautious addition of dry 
methanol (80 mL). The volatile material and methanol were removed and 50 
mL of methanol was added again, stirred, and evaporated under reduced 
pressure. The residue was purified by flash column chromatography eluting 
with 4% methanol in chloroform. A colorless liquid 39 was obtained in 91.4% 
yield (12.75 g) (Yoon et al., 1973; Ravid et al., 1978): TLC (methanoV 
chloroform, 4:96), R10.24; [aJn
24 
= +44.7° (c 0.26, CHC13); 1H NMR b 1.99-2.25 
(m, 2H), 2.39-2.60 (m, 2H), 3.51-3.60 (m, 2H), 3.75-3.82 (m, lH), 4.52-4.59 (m, 
lH); 13c NMR b 23.0, 28.5, 63.8, 80.9, 178.0. 
97 
4. (R)-(-)-y-Hydroxymethyl-y-butyrolactone 66 
This enatiomer was prepared from (R)-(-)-5-oxo-2-tetrahydrofuran-
carboxylic acid 65: TLC (methanol/chloroform, 4:96), R10.24; [a]D
24 
= -54.4° (c 
2.7, CHC13); 
1H NMR b 1.98-2.25 (m, 2H), 2.37-2.58 (m, 2H), 3.50-3.59 (m, 2H), 
3.77-3.83 (m, lH), 4.51-4.62 (m, lH); 13C NMR b 23.1, 28.5, 63.7, 81.0, 178.4. 
5. (SJ-(+ )-y-p-Tosyloxymethyl-y-butyrolactone 40 
A mixture of 39 (2,32 g, 20 mmol) and p-tosylchloride (5. 73 g, 30 mmol) 
in pyridine (4 mL) and methylene chloride (10 mL) was stirred at room 
temperature for 9 hr. At completion, the mixture was diluted with methylene 
chloride (80 mL), and the solution was washed with 10% HCl aq. solution (3 
x 50 mL), 20% NaHCO3 aq. solution (2 x 50 mL), and brine. The mixture was 
dried over N¾SO4. The drying agent was filtered and the filtrate was 
concentrated under reduced pressure. The product was crystallized from 
methylene chloride/diethyl ether to give the pure tosylate 40 in 93% yield 
(needle, 5.02 g) (Ho and Davies, 1983): TLC (diethyl ether), Rr 0.16; [a]D24 = 
+46.2° (c 2.5, CHC13), mp 86-87 °C; 1H NMR b 2.04-2.14 (m, lH), 2.25-2.37 (m, 
lH), 2.42 (s, 3H), 2.46-2.56 (m, 2H), 4.13 (ddd, J = 4.18, 8.69, 11.0 Hz, 2H), 
4.62-4.69 (m, lH), 7.34 (d, J = 8.3 Hz, 2H), 7.75 (d, J = 8.4 Hz, 2H); 13C NMR 
b 21.6, 23.5, 27.8, 69.9, 76.4, 127.9, 130.0, 132.3, 145.4, 175.9. 
98 
6. (R)-(-)-y-Tosyloxymethyl-ybutyrolactone 67 
From (R)-(-)-y-hydroxymethyl-y-butyrolactone (66): TLC (diethyl ether) 
Rr 0.16; mp 85-87 °C; [a]0 24 = -45.1° (c 2.6, CHC13); 1H NMR 6 2.01-2.12 (m, 
lH), 2.24-2.35 (m,lH), 2.44 (s, 3H), 2.45-2.55 (m, 2H), 4.12 (ddd, J = 4.19, 8.70, 
11.0 Hz, 2H), 4.61-4.68 (m, lH), 7.34 (d, J = 8.4 Hz, 2H), 7.76 (d, J = 8.4 Hz, 
2H); 13C NMR 6 21.5, 23.5, 27.6, 70.0, 76.5, 127.8, 130.0, 132.3, 145.3, 175.7. 
7. (SJ-(+ )-5-Az,ido-4-pentanolide 41 
To a solution of 40 (8.21 g, 30 mmol) in dry DMF (25 mL) was added 
NaN3 (6.5 g, 100 mmol) in portions and refluxed for 1.5 hr. The removal of 
solvent resulted in an oily residue (dark brown color) which was shaken with 
chloroform (50 mL) and filtered through a Celite pad. The pad was washed 
with hot chloroform (20 mL). The filtrate and washing were combined and 
concentrated in vacuo. Flash column chromatography (acetone/hexane, 1:4) 
afforded yellow liquid product 41 (3.98 g, 93%) (Olsen et al., 1985): TLC 
(acetone/ hexane, 1:4), Rr 0.09; IR (cm-1) 2120 (N3 stretching), 1780 (lactone 
carbonyl); [a]0 24 = +91.9° (c 5.0, CHC13); 1 H NMR 6 1.95-2.08 (m, lH), 2.23-
2.35 (m, lH), 2.44-2.64 (m, 2H), 3.49 (ddd, J = 3.62, 4.99, 13.3 Hz, 2H), 4.58-
4.65 (m, lH); 13C NMR 6 24.5, 28.1, 54.1, 77.9, 176.0. 
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8. (R)-(-)-5-Az,ido-4-pentanolide 68 
From (R)-(-)-(67), yielded 89.2%: TLC (acetone/hexane, 1:4), Rr 0.10; 
[aJn24 = -86.3° (c 2.5, CHC13); 1H NMR o 1.95-2.06 (m, lH), 2.22-2.34 (m, lH), 
2.44-2.65 (m, 2H), 3.47 (ddd, J = 3.62, 5.00, 13.4 Hz, 2H), 4.58-4.66 (m, lH); 
13c NMR o 24.5, 28.0, 54.2, 78.0, 175.9. 
9. (S)-(-)-5-Hydroxy-2-piperidinone 42 
(S)-(+)-(41) (1.44 g, 10.2 mmol) was dissolved in methanol (80 mL) and 
catalytic amount of 10% palladium on activated carbon was added. Whole 
mixture was shaken on a Parr Hydrogenator (H2, 50 psi) overnight. The 
solution was filtered through a Celite pad and the pad was washed with hot 
methanol (20 mL). The filtrate and washing were combined and concentrated 
under reduced pressure. Flash column chromatography was conducted using 
methano]/chloroform (1:9) to obtain 42 which was recrystallized from 
methano]/diethyl ethyl ether to give white crystals (1.15 g, 96%) (Olsen et al., 
1985): TLC (methanol/chloroform, 1:9), R10.16; mp 120-121 °C; [a]D
24 
= -12.4° 
(c 0.5, CH3OH); 1H NMR (D2O) o 1.74-1.82 (m, 2H), 2.13-2.36 (m, 2H), 3.13 
(dd, J = 3.9, 13.2 Hz, lH), 3.16 (sweak, lH), 3.29 (dd, J = 3.8, 13.2 Hz, lH), 3.53 
(dbr' lH), 3.98-4.04 (m, lH); 13C NMR (D2O, ref CD3OD: 49.0 ppm) o 26.4, 
26.6, 47.6, 62.5, 174.9. 
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10. (R)-( + )-5-Hydroxy-2-piperidinone 69 
From (R)-(-)-(68), yield (92%): mp 120-123 °C; [a]n24 = +13.3° (c 0.5, 
CH3OH); 1H NMR b 1.73-1.88 (m, 2H), 2.15-2.38 (m, 2H), 3.09 (dd, J = 3.9, 
13.2 Hz, lH), 3.19 (sweak' lH), 3.31 (dd, J = 3.8, 13.2 Hz, lH), 3.52 (dbrweak' 
' 
lH), 4.00-4.05 (m, lH); 13C NMR b 26.3, 26.5. 47.8, 62.7, 175.1. 
11. (S)-(-)-3-Hydroxypiperidine 43 
Method A. (S)-(-)-5-Hydroxy-2-piperidinone 42 (970 mg, 8.43 mmol) was 
stirred in 20 mL of dry THF at O °C under argon atmosphere. LiAlH4 (640 mg, 
2 eq) was added in portions and the ice bath was removed. The whole reaction 
mixture was refluxed for 43.5 hr. The reaction was diluted with ethyl acetate 
(50 mL) and a minimum amount of 0.1 M NaOH aq. solution was added to 
quench the excess reagent left over. The insoluble material was filtered and 
dried over N¾SO4. The drying agent was filtered and removal of solvent gave 
1.4 g of residue which was purified by flash column chromatography 
(methanol/chloroform, 3:7) to yield 43 (pale yellow crystal, 434 mg, 59.6%). 
Method B. To a suspension of the lactam 42 in dry THF (33.3 mg/mL), 
lM BH3 • THF complex in THF was injected at 0°C under argon atmosphere. 
The ice bath was removed and reaction mixture was refluxed for 1.5 hr. The 
reaction was quenched by cautious addition of anhydrous methanol and 
concentrated under reduced pressure. Same condition of column 
chromatography was conducted to yield 43 (48-62%): TLC (methanol 
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/chloroform, 3:7), Rr0.0l; mp 55-60 °C; [aJn24 = -8.94° (c 4.7, CH3OH); 1H NMR 
b 1.37-1.55 (m, 2H), 1.68-1.82 (m, 2H), 2.17 (shr' 2H), 2.61 (dd, J = 6.8, 11.9 Hz, 
lH), 2.63-2. 76 (m, 2H), 2.94 (dd, J = 2.5, 11.9 Hz, lH), 3.63-3.69 (m, lH); 13C 
NMR b 23.4, 32.9, 46.4, 53.5, 66.6. 
12. (R)-( + )-3-Hydroxypiperidine 70 
From (R)-(+)-(69): yield 58.3%; TLC (methanol/chloroform, 3:7), Rr0.0l; 
mp 56-60 °C; [a]D24 = +9.4° (c 0.65, CH3OH); 1H NMR b 1.38-1.59 (m, 2H), 
1.70-1.83 (m, 2H), 2.15 (sbr' 2H), 2.63 (dd, J = 6.8, 12.0 Hz, lH), 2.65-2.77 (m, 
2H), 2.93 (dd, J = 2.5, 12.0 Hz, lH), 3.65-3.70 (m, lH); 13C NMR b 23.6, 32.9, 
46.2, 53.5, 66.4. 
13. (SJ-(+ )-N-Cbz-3-Hydroxypiperidine 54 
Method A. (S)-(-)-3-Hydroxypiperidine 43 (1.012 g, 10 mmol) was stirred 
in 10 mL of water with 2 equivalent mole of powdered sodium bicarbonate 
(1.68 g). A solution of carbobenzylo:xy chloride (2.85 mL, 20 mmol) in toluene 
(8 mL) was added dropwise and pH was controlled to 8-9 by addition of 50% 
NaOH aq. solution. The solution was stirred overnight at room temperature. 
Diethyl ether (80 mL) was added and washed with water and sat'd NaCl aq. 
solution. Following treatment with N ¾SO 4, the drying agent was filtered, and 
concentrated by rotary evaporator. Flash column chromatography was 
conducted using petroleum ether/diethyl ether (2:3) to obtain a colorless oil (54) 
102 
(2.23 g, 88%). With commercially available racemic mixture (Fluka), this 
reaction completed in higher yield (90-95%). 
Method B. (from lactam 42). The (S)-(-)-lactam crystals (42) (415 mg, 3.6 
mmol) was stirred in dry THF (15 mL) at O °C under argon atmosphere. After 
a few minutes, 1 M BH3 • THF complex in THF (15 mL, 15 mmol) was injected 
slowly and the solution was heated (- 60 °C) for 1.5 hr. The reaction was 
quenched by cautious addition of methanol and removal of volatile material 
and solvent under reduced pressure gave yellowish oily crystals (piperidinol). 
The crude 3-hydroxypiperidine was dissolved in 7 mL of water, without further 
purification, and sodium bicarbonate (0.8 g) was added. Few minutes later, a 
solution of carbobenzyloxy chloride (1.4 mL) in toluene (5 mL) was added 
dropwise. After adjusting pH 8-9 with 50% NaOH aq. solution, the reaction 
was stirred overnight at room temperature. The work up process is same as 
described in method A, and 642 mg of 54 was yielded (overall yield 75.8%): 
TLC (petroleum ether/diethyl ether, 2:3), R10.l8; tR 7.29 min; [a]0
24 
= +5.79° 
(c 3.8, CHC13); 1H NMR b 1.38-1.59 (m, 2H), 1.71-1.93 (m, 2H), 3.08-3.28 (m, 
2H), 3.51-3.67 (hr, lH), 3.68-3.78 (br, lH), 3.76 (s, lH), 3.80-3.83 (m, lH), 5.23 
(s, 2H), 7.26-7.38 (m, 5H); 13C NMR b 22.2, 32.3, 44.1, 50.7, 66.0, 67.2, 126.9, 
128.0, 136.7, 155.7. 
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14. (R)-(-)-N-Cbz-3-Hydroxypiperidine 71 
From either (R)-(+)-(69) or (R)-(+)-(70), yield 85.4% (white oily crystal): 
TLC (petroleum ether/diethyl ether), R1 0.16; tR 7.28 min; [a]0 24 = -6.44° (c 
2.64, CHC13); 
1H NMR o 1.39-1.59 (m, 2H), 1.71-1.92 (m, 2H), 3.09-3.28 (m, 
2H), 3.51-3.66 (br, lH), 3.68-3.79 (br, lH), 3.75 (s, lH), 3.80-3.84 (m, lH), 5.23 
(s, 2H), 7.26-7.38 (m, 5H); 13C NMR o 22.2, 32.1, 44.0, 50.8, 66.1, 67.3, 126.8, 
128.1, 136.7, 155.7 
15. (S)-(-)-N-Cbz-3-Acetoxypiperidine 55 
The colorless oil 54 (1.12 g, 4. 76 mmol) was dissolved in 1 mL of 
pyridine and catalytic amount of DMAP (N,N-dimethylaminopyridine) was 
added. The mixture was stirred at room temperature under argon atmosphere. 
Anhydrous acetic anhydride (0.6 mL, 6.4 mmol) was injected and stirred for 3 
hr. Ethyl acetate (40 mL) was added and washed with 20% NaHCO3 and sat'd 
NaCl aq. solution. After dried over Na2SO4, filtered, and solvent was removed 
by rotary evaporator. The residue was purified by flash column 
chromatography using petroleum ether/diethyl ether (1:1) to yield 1.12 g 
(84.8%) of colorless liquid 55: TLC (petroleum ether/diethyl ether, 1:1), R10.21; 
~ 10.10 min; [a]0 24 = -10.5° (c 4.0, CHC13); 1H NMR o 1.43-1.60 (m, lH), 1.63-
1.90 (m, 3H), 1.98 (sbr' 3H), 3.29-3.43 (m, lH), 3.45-3.67 (m, 3H), 4. 72-4.86 (m, 
lH), 5.13 (sbr' 2H), 7.25-7.38 (m,5H); 13C NMR o 20.9, 21.8, 28.9, 44.0, 47.3, 
67.0, 67.7, 127.7, 127.9, 128.4, 136.7, 155.4, 170.2. Anal. calcd for C15H19NO4 
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: C, 64.97; H, 6.91; N, 5.05. Found: C, 64.93; H, 6.91; N, 5.10. 
16. (R)-( + )-N-Cbz-3-Acetoxypiperidine 72 
From (R)-(-)-(54), yielded 82.6%: TLC (petroleum ether/diethyl ether, 
1:1), Rr0.20; ½i 10.09 min; [a]n24 = +11.2° (c 4.3, CHC13); 1H NMR b 1.43-1.60 
(m, lH), 1.63-1.90 (m, 3H), 1.98 (8hr, 3H), 3.29-3.43 (m, lH), 3.45-3.67 (m, 3H), 
4.72-4.86 (m, lH), 5.13 (sbr' 2H), 7.25-7.38 (m,5H); 13C NMR b 20.9, 21.8, 28.9, 
44.0, 47.3, 67.0, 67.7, 127.7, 127.9, 128.4, 136.7, 155.4, 170.2. 
17. (S)-(-)-3-Acetoxypiperidine 51 
To a solution of 55 (1.01 g, 3.64 mmol) in methanol (80 mL) was added 
a catalytic amount of 10% palladium on activated carbon. The mixture was 
shaken under 35 psi of hydrogen on a Parr Hydrogenator. The catalyst was 
filtered through a Celite pad and the pad was washed with 10 mL of methanol. 
The filtrate and washing were combined and concentrated under reduced 
pressure. Flash column chromatography was conducted with chloroform/ 
methanol (9:1) to give colorless liquid 51 (468 mg, 89.8%): TLC (chloroform 
/methanol, 9:1), Rr 0.10; ½i 4.49 min; [a]n24 = -8.43° (c 7.0, CHC13); 1H NMR 
b 1.37-1.55 (m, 2H), 1.55-1.78 (m, 2H), 1.82-1.93 (m, lH), 2.01 (s, 3H), 2.63-2.75 
(m, 3H), 2.96-3.08 (dbr' lH), 4.67-4.76 (m, lH); 13C NMR b 21.3, 24.2, 29.6, 
45.9, 50.1, 69.6, 170.5. Anal. Calcd for C7H13N02: C, 58.67; H, 9.15; N, 9.78. 
Found: C, 58.81; H, 9.16; N, 9.64. 
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18. (R)-( + )-3-Acetoxypiperidine 73 
From (R)-(+)-(72),yield (85.4%): TLC (chloroform/methanol, 9:1),R10.10; 
tR 4.48 min; [aJn24 = +9.14° (c 5.8, CHC13); 1H NMR o 1.35-1.54 (m, 2H), 1.55-
1.80 (m, 2H), 1.83-1.95 (m, lH), 2.02 (s, 3H), 2.65-2.76 (m, 3H), 2.95-3.06 (dbr' 
lH), 4.67-4.77 (m, lH); 13C NMR o 21.2, 24.1, 29.5, 46.0, 50.0, 69.4, 170.6. 
19. (S)-(-)-N-(2-Hydroxyethyl)-3-acetoxypiperidine 58 
The colorless liquid 51 (400 mg, 2.79 mmol) was stirred in methanol (20 
mL) at ice-bath temperature. Few minutes later, ethylene oxide was bubbled 
into the solution and the proceeding of the reaction was monitored by TLC. 
Reaction was stopped when the formation of the overalkylated quaternary 
ammonium was monitored and the excess ethylene oxide was degassed, and 
the solution was concentrated in vacuo. Flash column chromatography using 
methanol/chloroform (2:98) afforded colorless liquid 58 (334 mg, 63.9%): TLC 
(methanol/chloroform, 1:9), Rr 0.29; tR 6.49 min; [a]D 24 = -24.0° (c 0.9, CHC13), 
1H NMR o 1.40-1.57 (m, 2H), 1.70-1.83 (m, 2H), 2.00 (s, 3H), 2.20-2.30 (m, 2H), 
2.47-2.51 (t, J = 5.9 Hz, 2H), 2.53-2.58 (m, lH), 2.72-2.77 (dd, J = 3.4, 11.0 Hz, 
2H), 3.53-3.56 (t, J = 5.9 Hz, 2H), 4.76-4.84 (m, lH); 13C NMR o 21.2, 22.7, 
29.3, 53.0, 56.9, 57.7, 59.1, 69.4, 170.4. Anal calcd for C9H 17NO3: C, 57.73; H, 
9.15; N, 7.48. Found: C, 57.62; H, 9.11; N, 7.19. 
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20. (R)-( + )-N-(2-Hydroxyethyl)-3-acetoxypiperidine 75 
From (R)-( + )-3-acetoxypiperidine 73, yielded 58.8%: TLC (methanol / 
chloroform, 1:9), Rr 0.30; tR 6.48 min; [a]0 24 = +22.1 ° (c 1.1, CHC13); 1H NMR 
{) 1.41-1.58 (m, 2H), 1.70-1.83 (m, 2H), 1.99 (s, 3H), 2.20-2.29 (m, 2H), 2.49 (t, 
J = 5.9 Hz, 2H), 2.53-2.58 (m, lH), 2.75 (dd, J = 3.4, 11.0 Hz, 2H), 3.55 (t, J 
= 5.9 Hz, 2H), 4.76-4.84 (m, lH); me NMR {) 21.2, 22.8, 29.3, 52.9, 57.0, 57.7, 
59.1, 69.4, 170.5. 
21. (S,S)-( + )-N-(2-Hydroxypropyl)-3-acetoxypiperidine 59 
(S)-(-)-3-acetoxypiperidine 51 (578 mg, 4.0 mmol) was stirred in 
methanol (5 mL) at 5°C. (S)-(-)-propylene oxide (0.4 mL, 5.7 mmol) was added 
dropwise and the reaction was stirred for 14-17 hr at 5 °C. At completion, the 
volatile material and methanol were removed under reduced pressure, then the 
residue was purified by flash column chromatography using diethyl ether as 
eluting system to yield (S,S)-(+)-(59) (612 mg, 76%). TLC (diethyl ether), Rr 
0.25; tR 6.65 min; [a]0 24 = +24.4° (c 3.6, CHC13); 1 H NMR {) 1.07 (d, J = 6.2 Hz, 
3H), 1.39-1.60 (m, 2H), 1.67-1.84 (m, 2H), 1.99 (s, 3H), 2.11-2.22 (m, 2H), 2.28 
(dd, J = 3.l, 12.5 Hz, lH), 2.42 (tbr' J = 5.3 Hz, 2H), 2.86 (dd, J = 3.2, 11.0 Hz, 
lH), 3.72-3.80 (m, lH), 4.78 (ton dd, J = 7.8, 7.9, 15.7 Hz, lH); me NMR {) 
19.9, 21.2, 22.7, 29.2, 52.8, 57.5, 62.2, 65.5, 69.2, 170.4. Anal calcd for 
C10H19NO3: C, 59.68; H, 9.52; N, 6.96. Found: C, 59.63, H, 9.54, N, 6.92. 
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22. (R,R)-(-)-N-(2-Hydroxypropyl)-3-acetoxypiperidine 77 
This enantiomer of (S,S)-( + )-(59) was obtained from (R)-( + )-3-acetoxy-
piperidine 73 and (R)-(+)-propylene oxide (68% yield): TLC (diethyl ether), Rr 
0.25; tR 6.64 min; [a]n24 = -22.6° (c 3.4, CHC13); 1H NMR b 1.07 (d, J = 6.2 Hz, 
3H), 1.40-1.61 (m, 2H), 1.68-1.85 (m, 2H), 2.00 (s, 3H), 2.11-2.23 (m, 2H), 2.27 
(dd, J = 3.2, 12.5 Hz, lH), 2.42 (tbr' J = 5.2 Hz, 2H), 2.86 (dd, J = 3.2 Hz, 11.2 
Hz, lH), 3.71-3.79 (m, lH), 4.79 (ton dd, J = 7.8, 8.0, 15.6 Hz, lH); 13C NMR 
b 20.0, 21.2, 22.6, 29.1, 53.0, 57.5, 62.3, 65.6, 69.4, 170.5. 
23. (S,R)-( + )-N-(2-Hydroxypropyl)-3-acetoxypiperidine 76 
This diastereoisomer of (S,S)-( + )-(59) was obtained from the reaction of 
(R)-(+ )-3-acetoxypiperidine 73 and (S)-(-)-propylene oxide (yield 71 %): TLC 
(diethyl ether), Rr 0.19; ~ 6.64 min; [aJn24 = +73.3° (c 3.6, CHC13); 1H NMR 
b 1.08 (d, J = 8.3 Hz, 3H), 1.41-1.56 (m, 2H), 1.72-1.84 (m, 2H), 2.00 (s, 3H), 
2.10-2.19 (m, 2H), 2.31 (dd, J = 3.1, 12.3 Hz, lH), 2.44 (~r' J = 7.6 Hz, lH), 
2.62-2.72 (m, 2H), 3.73-3.79 (m, lH), 4.82 (ton dd, J = 7.7, 7.8, 15.3 Hz, lH); 
13C NMR b 19.9, 21.2, 22.7, 29.2, 52.8, 57.5, 62.2, 65.5, 69.2, 170.4. 
24. (R,S)-(-)-N-(2-Hydroxypropyl)-3-acetoxypiperidine 60 
From (S)-(-)-3-acetoxypiperidine 51 and (R)-( + )-propylene oxide (yield 
78%): TLC (diethyl ether), Rr 0.14; ~ 6.55 min; [a]D 24 = -68.9° (c 6.3, CHC13); 
1H NMR b 1.10 (d, J = 8.2 Hz, 3H), 1.42-1.56 (m, 2H), 1.72-1.84 (m, 2H), 2.01 
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(s, 3H), 2.10-2.20 (m, 2H), 2.31 (dd, J = 3.2, 12.4 Hz, lH), 2.45 (~r' J = 7.6 Hz, 
lH), 2.63-2.72 (m, 2H), 3.74-3.81 (m, lH), 4.82 (ton dd, J = 7.6, 7.8, 15,4 Hz, 
lH); 13C NMR o 20.0, 21.2, 22.6, 29.4, 52.6, 57.6, 62.2, 65.6, 69.3, 170.3. 
25. (S)-(-)-N-(2-Chloroethyl)-3-acetoxypiperidine 61 
(S)-(-)-(58) (373 mg, 2.0 mmol) was stirred in dry methylene chloride (6 
mL) at 5 °C under argon atmosphere. Freshly distilled thionyl chloride (0.16 
mL, 2.2 mmol) was injected and stirred for 20 min. The cooler was removed 
and the reaction was allowed to stir for more 3 hr at room temperature. At 
completion, the reaction was diluted by addition of methylene chloride (10 mL), 
and chilled at ice bath temperature. Addition of dry diethyl ether resulted in 
crystallization of hydrochloride salt. The salt was filtered and washed with 
dry diethyl ether. Removal of the last trace of the solvent in vacuo gave white 
crystals of (S)-(-)-(61) hydrochloride salt (408 mg, 80.4%). The (S)-(-)-(61) 
hydrochloride salt was redissolved in methylene chloride (10 mL) and excess 
amount of sodium bicarbonate was added. Vigorous stirring resulted in free 
base (tertiary amine) which was purified by flash column chromatography 
using petroleum ether and diethyl ether (1:1): TLC (petroleum ether/diethyl 
ether, 1:1), Rf 0.34; [aJn24 = -31.1 ° (c 0.45, CHC13); 1H NMR o 1,38-1.46 (m, 
lH), 1.52-1.62 (m, lH), 1.71-1.87 (m, 2H), 2.03 (s, 3H), 2.25-2.34 (m, 2H), 2.56-
2.63 (m, lH), 2.73 (t, J = 7.2 Hz, 2H), 2.80 (ddhr' J = 3.55, 10.9, Hz, lH), 3.54 
(t, J = 7.2 Hz, 2H), 4.82 (ton dd, J = 7.8, 8.2, 15.9 Hz, lH); 13C NMR o 21.3, 
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22.6, 29.2, 40.8, 53.3, 56.9, 59.7, 69.3, 170.5. Anal calcd for C9H16NO2Cl: C, 
52.55; H, 7.84; N, 6.81. Found: C, 52.55; H, 7.86; N, 6.74. 
26. (R)-( + )-N-(2-Chloroethyl)-3-acetoxypiperidine 78 
From (R)-(+)-(75): Rf 0.35; [a]0 24 = +28.3° (c 0.50, CHC13); 1H NMR b 
1.38-1.46 (m, lH), 1.51-1.63 (m, lH), 1.72-1.88 (m, 2H), 2.02 (s, 3H), 2.26-2.33 
(m, 2H), 2.55-2.62 (m, lH), 2.73 (t, J = 7.2 Hz, 2H), 4.80 (ton dd, J = 7.8, 8.2, 
16.0 Hz, lH); 13C NMR b 21.4, 22.6, 29.6, 41.0, 53.1, 57.1, 59.9, 69.5, 170.4. 
Reaction of N-(2-hydroxypropyl)-3-acetoxypiperidine with thionyl chloride 
General procedure; Each diastereoisomer of N-(2-hydro:xypropyl)-3-acetoxy-
piperidine was stirred in dry methylene chloride (50 mg/ mL) at 0 °C under 
argon atmosphere. Few minutes later freshly distilled thionyl chloride (1.5 
equiv) was injected and the reaction mixture was stirred for 20 min. The 
cooler was removed and the reaction was allowed to stir 5 more hr at room 
temperature. With stirring, addition of dry diethyl ether caused crystallization 
of hydrochloride salt. Filtered and recrystallization from methylene 
chloride/diethyl ether afforded white crystals (71-84%). Treatment with base 
and a flash column chromatography using petroleum ether and diethyl ether 
(3:1) as eluting system afforded tertiary amines 62, 63, 79, and 80. Anal calcd 
for C10H18NO2Cl: C, 54.66; H, 8.26; N, 6.38. Found: C, 55.00; H, 8.10; N, 6.21. 
110 
27. (S,S)-(-)-N-(2-Chloropropyl)-3-acetoxypiperidine 62 
mp 134-137 °C (HCl salt); TLC (petroleum ether/diethyl ether, 3:1), Rr 
0.32; [aJn24 = -43.0 (c 2.6, CHC13); 1H NMR {} 1.29-1.41 (m, lH), 1.47 (d, J = 
6.4 Hz, 3H), 1.51-1.62 (m, lH), 1.66-1.77 (m, lH), 1.79-1.89 (m, lH), 2.01 (s, 
3H), 2.19-2.29 (m, 2H), 2.46 (dd, J = 7.4, 13.1 Hz, lH), 2.55-2.61 (m, lH), 2.63 
(dd, J = 6.4, 13.1 Hz, lH), 2.80 (ddbr, J = 3.9, 10.8 Hz, lH), 4.01 (dq, J = 6.7, 
13.2 Hz, lH), 4. 78 (t on dd, J = 8.3, 8.6, 16.8 Hz, lH); 13C NMR {} 21.2, 22.9, 
23.2, 29.4, 53.8, 54.6, 57.2, 66.1, 69.5, 170.4. 
28. (R,R)-( + )-N-(2-Chloropropyl)-3-acetoxypiperidine 79 
mp 133-137 °C (HCl salt); TLC (petroleum ether/diethyl ether, 3:1), Rr 
0.31; [a]n24 = +30.0° (c 1.8, CHC13); 1H NMR {} 1.31-1.41 (m, 2H), 1.47 (d, J = 
6.54 Hz, 3H), 1.51-1.63 (m, lH), 1.68-1.75 (m, lH), 1.79-1.87 (m, lH), 2.01 (s, 
3H), 2.20-2.30 (m, 2H), 2.47 (dd, J = 7.3, 13.1 Hz, lH), 2.55-2.64 (m, lH), 2.64 
(dd, J = 6.4, 13.1 Hz, lH), 2.78-2.83 (m, lH), 3.96-4.05 (m, lH), 4.78 (ton dd, 
J = 8.2, 8.5, 16. 7 Hz, lH); 13C NMR {} 21.3, 22.8, 23.2, 29.4, 53.8, 54.6, 57.2, 
66.1, 69.5, 170.4. 
29. (S,R)-(-)-N-(2-Chloropropyl)-3-acetoxypiperidine 80 
mp 153-155 °C (HCl salt); TLC (petroleum ether/diethyl ether, 3:1), Rr 
0.33; [aJn24 = -21.1° (c 0.9, CH3OH) (HCl salt); 1H NMR {} 1.31-1.41 (m, 2H), 
1.47 (d, J = 6.54 Hz, 3H), 1.51-1.63 (m, lH), 1.68-1.75 (m, lH), 1.79-1.87 (m, 
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lH), 2.01 (s, 3H), 2.20-2.30 (m, 2H), 2.47 (dd, J = 7.3, 13.1 Hz, lH), 2.55-2.64 
(m, lH), 2.64 (dd, J = 6.4, 13.1 Hz, lH), 2. 78-2.83 (m, lH), 3.96-4.05 (m; lH), 
4.78 (ton dd, J = 8.2, 8.5, 16.7 Hz, lH); 13C NMR b 21.3, 22.8, 23.2, 29.4, 53.8, 
54.6, 57.2, 66.1, 69.5, 170.4. 
30. (R,S)-( + )-N-(2-Chloropropyl)-3-acetoxypiperidine 63 
mp 152-154 °C (HCl salt); [a]0 24 = +24.2° (c 1.2, CH3OH) (HCl salt); 1H 
NMR b 1.31-1.41 (m, 2H), 1.47 (d, J = 6.54 Hz, 3H), 1.51-1.63 (m, lH), 1.68-
1.75 (m, lH), 1.79-1.87 (m, lH), 2.01 (s, 3H), 2.20-2.30 (m, 2H), 2.47 (dd, J = 
7.3, 13.1 Hz, lH), 2.55-2.64 (m, lH), 2.64 (dd, J = 6.4, 13.1 Hz, lH), 2.78-2.83 
(m, lH), 3.96-4.05 (m, lH), 4.78 (ton dd, J = 8.2, 8.5, 16.7 Hz, lH); 13C NMR 
b 21.3, 22.8, 23.2, 29.4, 53.8, 54.6, 57.2, 66.1, 69.5, 170.4. 
31. (S)-(-)-N,N-Dimethyl-3-acetoxypiperidinium iodide 21 
To a solution of (S)-(-)-3-acetoxypiperidine 51 (430 mg, 3.0 mmol) in 
anhydrous methanol (3 mL), methyl iodide (1 mL, excess) was added dropwise 
at room temperature. At completion, the reaction mixture was diluted with 
methanol (12 mL). With stirring, addition of anhydrous diethyl ether afforded 
white powdery crystals of 21 in 65% yield: mp 165-168 °C; [a] 0 24 = -3.36° (c 
0.4, CHC13); 
1H NMR b 1.90-2.05 (m, 2H), 2.10 (s, 3H), 2.07-2.22 (m, 2H), 3.50 
(s, 3H), 3.55 (s, 3H), 3.71-3.83 (m, 2H), 3.97-4.08 (m, lH), 4.16 (dd, J = 3.3, 
13.5 Hz, lH), 5.22-5.28 (m, lH); 13C NMR b 17.13, 21.24, 25.33, 53.13, 55.40, 
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62.19, 63.44, 65.28, 169.31. 
32. (R)-( + )-N,N-Dimethyl-3-acetoxypiperidinium iodide 7 4 
From (R)-(+)-3-acetoxypiperidine 73, yield 61%: mp 166-169 °C; [a]n24 
= +3.82° (c 0.5, CHCl3); 1H NMR o 1.90-2.04 (m, 2H), 2.09 (s, 3H), 2.07-2.21 (m, 
2H), 3.50 (s, 3H), 3.56 (s, 3H), 3.70-3.82 (m, 2H), 4.01-4.09 (m, lH), 4.13 (dd, 
J = 3.4, 13.5 Hz, lH), 5.20-5.25 (m, lH); 13C NMR o 17.14, 21.24, 25.34, 53.14, 
55.40, 62.18, 63.45, 65.30, 169.33. 
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Part II. Fractional Recrystallization 
33. (R,R)-( + )-Diacetoxysuccinic anhydride 83 
(+)-Tartaric acid (15.09 g, 0.1 mol) was placed in 250 mL round bottom 
flask and connected to a condenser. The condenser was attached to an 
additional funnel and covered with an argon balloon. A solution of acetic 
anhydride (40 mL) and sulfuric acid (1.0 mL) was added dropwise with stirring 
at 0°C. At completion of addition, the cooler was removed and the mixture was 
refluxed for 30 min. Cooling at room temperature resulted in a solid residue. 
The solidified residue was shaken with benzene (100 mL) and filtered. The 
crystals were washed with dry ethyl ether. Removal of the last trace of solvent 
under vacuum afforded white crystals 83 in 76% yield: mp 133-135 °C (dee.) 
(lit. 133-134 °C); [a]0 24 = +97.2° (c, 0.5, CHC13); 1H NMR o 2.21 (s, 6H), 5.66 
(s, 2H); 13c NMR o 20.16, 22.19, 72.07, 163.09, 169.50. 
34. (S,8)-(-)-Diacetoxysuccinic anhydride 84 
This enantiomer of 83 was prepared from (-)-tartaric acid: mp 133-134 
°C; [a]0 24 = -98.5° (c, 0.5, CHC13); 1 H NMR o 2.22 (s, 6H), 5.67 (s, 2H); 13c 
NMR o 20.15, 22.19, 72.08, 163.09, 169.51. 
35. (R,R)-( + )-4-Chlortartranilic acid 85 
To a solution of 83 (10 g, 46.3 mmol) in dry methylene chloride (50 mL), 
4-chloroaniline (6.0 g, 47 mmol) was added portionwise and whole solution was 
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refluxed for 15 hr. After cooling, the dark brown solution was washed with 3 
equivalents of potassium hydroxide aqueous solution and the washings were 
combined and neutrallized by addition of cone. HCl resulting precipitation of 
crude product. The wet crystals were recrystallized from ethanol/water to 
obtain needle-shaped colorless crystals 85 in 68% yield: mp 192-194 °C (dee.); 
1H NMR b 3.50-4.20 (hr, 2H), 4.57 (s, lH), 4.67 (s, lH), 5.11-5.40 (hr, lH), 7.34 
(d, J = Hz, 2H), 7.80 (d, J = Hz, 2H), 9.32 (s, lH); 13C NMR b 72.67, 74.25, 
121,75, 129.31, 170.45, 173.44. 
36. (S,S)-(-)-4-Chlorotartranilic acid 86 
Prepared from 84: mp 193-195 °C (dee.); 1H NMR b 3.50-4.21 (hr, 2H), 
4.58 (s, lH), 4.66 (s, lH), 5.10-5.39 (hr, lH), 7.34 (d, J = Hz, 2H), 7.81 (d, J = 
Hz, 2H), 9.35 (s, lH); 13C NMR b 72.66, 74.25, 121. 72, 129.27, 170.44, 173.46. 
37. Fractional recrystallization of the diastereomeric salts and recovery of 
optically pure 3-piperidine from its diastereomeric salt. 
(+)-(+)-salt: To a solution of (+/-)-3-hydroxypiperidine in warm 95% 
ehtanol, a solution of 0.5 equivalent of (+)-4-chlorotartranilic acid 85 in 95% 
ethanol was added. Stirred at 40 °C to obtain clear solution state, then cooled 
to room temperature. Standing overnight at room temperature yielded needle-
shaped crystals in 70-74% yield: mp 153-156 °C. 
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(-)-(-)-salt: Obtained from (-)-4-chlorotartranilic acid 86: mp 152-156 °C. 
Each diastereomeric salt was dissolved in methanol/toluene (3:7) and 
equivalent amount of potassium carbonate was added. After vigorous stirring 
for 3 hr, filtered, and the filtrate was concentrated in vacuo to give a waxy 
solid residue. The residue was shaken with hot ethyl acetate and 
concentrated. Crystallization from ethyl acetate/benzene/hexane gave pale 
yellow crystals (powdery) of (S)-(-)- or (R)-( + )-3-hydroxypiperidine in 56-62% of 
recovery. 
APPENDIX 
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